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CHAPTER I.  
 
Introduction 
 
Musculoskeletal Diseases 
 
 Musculoskeletal disorders are a common occurrence throughout the United States 
as they can derive from several factors such as osteoporosis, arthritis, injuries, and 
infantile developmental conditions.  Of self-reported primary medical conditions of 
adults in 2005, 48.3% involve a musculoskeletal disorder creating a huge impact on the 
economy due to lost work days
1-3
.  This number is expected to grow as the U.S. 
population continues to age
1
.  Former president George W. Bush declared the years of 
2002-2011 as the United States Bone and Joint Decade in March 2002
1
.  The challenge of 
developing strategies to combat this multifaceted problem crosses all scientific 
disciplines.  In this work, a novel biomaterial for bone tissue engineering will be 
discussed as a treatment to help alleviate the burden of musculoskeletal diseases globally.  
Bone Biology  
 
Bone is a dynamic tissue that fulfills a critical role in the proper function of the 
body.  As a major part of the skeletal system, bone has five major functions
4
:  support, 
protection, movement, hematopoiesis, and mineral/energy storage.  Bone forms the 
framework of the body that supports and protects the organs and soft tissues.  In 
conjunction with muscle contraction, bones are levers that allow for movement around 
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joints.  Red bone marrow cells in conjunction with platelets are formed within bone.  
Furthermore, bone stores both calcium and phosphorus that can be released as needed to 
other locations in the body
5,6
.  Bone can also store energy as adipose cells of yellow bone 
marrow are also able to store energy within lipids. 
There are four major categories of bone
4
: long, short, flat, and irregular.  Long 
bones are typically found in the appendages, while short bones are found in small, 
compact spaces in the body.  The shaft of long bones consists of the diaphysis, and each 
end of the bone is referred to as the epiphysis.  These regions comprise of either 
cancellous (spongy) and cortical (compact) bone.  Cortical bone surrounds cancellous 
bone in both epiphyseal regions.  Cancellous bone, which contains red bone marrow,  is a 
cell-rich region and it constantly undergoes remodeling
7
.  The diaphysis, separated from 
the epiphysis by the epiphyseal line, contains the medullary cavity that has yellow blood 
marrow and nutrient vessels within it. The inner wall of this cavity is lined with a layer of 
connective tissue called the endosteum, and the outer wall is similarly covered with dense 
regular connective tissue to form the periosteum
4
.  Cortical bone has a compressive 
strength and modulus in the range of 130-180 MPa and 12-18 GPa, respectively
8,9
.  In 
contrast, cancellous bone has a compressive strength and modulus range of 4-12 MPa and 
0.1-0.5 GPa, respectively.  Flat bones are found around the skull and ribs.  Odd shaped 
bones such as vertebrae comprise the irregular bones.     
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Figure I.1: Diagram of long bone.   
 
Bone is a natural composite matrix that comprises of 70-80 wt% inorganic 
material, 20 wt% organic material, and a remaining balance of water
6,10,11
.  Although 
cells and blood vessels comprise bone, the actual bone matrix is more than 90% of the 
total tissue
6
.  Collagens are the predominant organic component in the bone matrix, 
which contribute to the tensile strength and flexibility of bone
6,11
.    Growth factors such 
as bone morphogenetic protein, a protein that controls and supports the activity of bone 
cells, are also found in the bone matrix.  Collagen in encompassed by the mineral of the 
inorganic matrix, containing apatite, carbonate ions, and acid phosphate groups
6
.  The 
mineral phase of the bone matrix is responsible its hardness and stiffness
7,11
as well as its 
ion storage capabilities
5,6
.  These ions are important in key biochemical reactions such as 
nerve conduction and muscle contraction
6
.   
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Multiple cells are involved in bone formation; however, osteoblasts, osteoclasts, 
and osteocytes are three essential cells that have a direct role in maintaining critical 
balance of bone remodeling.  Osteoblasts derive from ostoprogenitor cells that are found 
in bone canals, endosteum, and periosteum
6
. They are bone forming cells that are 
responsible for synthesis of the bone matrix as well as the regulation of the mineralization 
process
6,10,12
.  By tightly aligning themselves on the surface of new bone, osteoblasts 
deposit new mineral.  The unmineralized organic matrix that is secreted by the 
osteoblasts is called osteoid
6,7
.  Osteoid is composed of 90% type I collagen and other 
bone proteins such as lipids
7
.  Once surrounded by newly formed mineral matrix, 
osteoblasts differentiate into osteocytes, which form more than 90% of the cell 
population in adult bone
6,12
.  Their oval shapes allow them to have contact with other 
cells, providing an intricate communication system throughout bone 
7,12
.  This 
communication system allows them to conduct cell-mediated mineral exchange as well as 
ion exchange
6,12
.  Osteoclasts, the largest of the bone cells, are responsible for the 
resorption of bone.  Stimulated monocytes are fused together to form multi-nucleated 
osteoclasts, which can have three to twenty nuclei
6
.  Osteoclasts have ruffled borders 
which gives them increased surface area to resorb bone.  Osteoclasts bind themselves to 
the surface of bone and pump transport protons into the sealed space reducing the pH 
from 7 to 4, which solubilizes the bone mineral
6
.  Osteoclasts have the capability to 
divide into mononuclear cells once it has completed its resorption activity
6
. 
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Figure I.2: Critical Cells involved in bone formation and resorption.   
 
Remodeling after Injury 
 
The healing mechanism of bone is dependent upon the site and type of injury.  
The healing of long bone fractures provides a generic process of the bone healing, which 
occurs in three overlapping phases: the early inflammatory stage, the repair stage, and the 
late remodeling stage
7
.  In the early inflammatory stage, inflammatory cells such as 
monocytes and macrophages, invade the bone defect.  Granulation tissue, temporary 
connective tissue,  along with vascular tissue is formed and mesenchymal cells begin to 
migrate to the defect
7,13
.  Fibroblasts begin to lay down stroma, and a callus, a 
mineralized collagen matrix, is formed around the repair site.  The callus eventually 
transitions to woven bone, which is immature bone with randomly arranged collagen 
bundles.  Woven bone is weak with respect to mature bone due to its lack of collagen 
organization
11,13,14
.    During the late remodeling stage, woven bone is replaced with 
mature and subsequently strength is restored.  The remodeling is guided by mechanical 
stress, and the duration of this stage can be from months to years
7,13
.   
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Table I.1: Cell types involved during bone repair. 
cell type function 
osteoblasts responsible for the production of the bone matrix 
osteoclasts multinucleated giant cells with resorbing activity of mineralized tissue 
osteocytes 
mature osteoblasts within the bone matrix; responsible for bone 
maintenance  
fibroblasts responsible for synthesizing cartilage and extracellular matrix 
monocytes precursors to macrophages that are part of an immune response 
macrophages mononuclear cells that remove dead cell material 
mesenchymal stem 
cells undifferentiated cells that are precursors to the ostoblast cell type 
 
Treatment 
 
 Substantial bone defects typically require treatment to facilitate proper healing.  
Furthermore, critical size defects will not heal without the aid of a biomaterial.  Such 
biomaterials facilitate new bone formation via the following mechanisms: osteogenesis, 
osteoinduction, and osteoconduction.  Osteogenesis involves the direct formation of bone 
matrix by osteoblasts already present in the biomaterial.  Osteoinductive biomaterials 
stimulate bone formation via paracine signaling, communication of cells within the same 
proximity, from bone growth factors that are incorporated in the biomaterial.  A 
biomaterial that acts as a scaffold, supporting cell adhesion, for new bone formation is 
osteoconductive.  Biomaterials may possess a combination of these mechanisms.   
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Table I.2: Terms used to describe biomaterials in bone tissue engineering. 
term definition  
biocompatibility the lack of immunogenic response 
osteoconductivity the quality of a porous interconnected structure that permits new cells to 
attach, 
 proliferate, and migrate 
osteoinductivity possessing the necessary proteins and growth factors that induce the 
progression of 
 precursors toward osteblast lineage 
osteointegration a newly formed intimate bond with the implant and material  
 
Bone derived graft is a common treatment that is used to treat defects.  There are 
three categories of bone grafts: autograft, allograft, and xenograft.  Autograft bone, 
considered the gold standard of treating bone defect, is a graft that is transplanted from 
one site to another site of the same individual.  In general, autograft bone is considered to 
be osteogenic, but this is highly dependent upon the source of the autograft.  Factors such 
as health and quality of bone can significantly affect the remodeling properties of 
autograft
15
.  Cancellous autograft is porous and contains abundant host vessels and 
osteoblasts
16
.  In contrast, cortical autograft is less porous and contains less osteoblasts 
than cancellous autograft, making it less osteogenic
15
.  However, the strategy of using 
vascularized cortical autograft improves the osteogenic properties of the graft as it more 
resembles natural bone
15
.  As more studies continue to show the safety of allograft 
bone
17
, allograft bone is becoming an attractive option to treat defects.  Allograft bone 
does not remodel via osteogenesis; however, it possesses osteoinductive properties with 
appropriate processing.  Osteoinductive proteins can still be present in allograft 
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demineralized bone matrix (DBM) with the appropriate sterilization and storage 
techniques
17,18
.  Cortical allograft bone is only osteoconductive as it has few cells or bone 
matrix proteins within its mineral matrix
7,15
.  However, it possesses high initial strength 
due to its mineral content.  Xenograft bone is transplanted between different species.  
Several studies have shown that xenograft bone is biocompatible as well as 
osteoconductive
19-21
. 
Bone Derived Graft Substitutes 
 As an alternative to bone grafts, several substitutes have been developed to mimic 
the properties of autograft.  Thus, graft substitutes should be biocompatible, 
biodegradable, and possess mechanical integrity.  In addition, the bone graft substitute 
should have an adequate shelf life, easily processed, and easily sterilized
22
.  Multiple 
optional factors can enhance the performance of graft substitutes such as injectability, 
porosity, and incorporation of biologics such as growth factors.  With all of these 
considerations in mind, several platforms have been used to obtain these properties.   
Biodegradable Polymers 
 There are multiple natural and synthetic materials polymers that have been 
developed to treat bone defects.  These materials are attractive as a biomaterial as they 
typically derive from natural resources with a reliable source of raw materials.  Polymers 
are divided into two categories: natural and synthetic.  Natural polymers such as type I 
collagen and hyaluronic acid have varying degradation times and are degraded through 
enzymatic mechanisms
23,24
.  Type I collagen has mechanical properties in the range of 
trabecular bone, while hyaluronic acid has properties below it
23
.  Polyesters such as 
poly(glycolide) (PGA), poly(lactide) (PLA), poly(glycolide) (PGA) and poly(-
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caprolactone) (PCL) have been well studied as biodegradable orthopedic devices
22
.  In 
clinical use, PLA and PGA have an established safe history with the FDA  as several 
commercial products derived from these polymers have been approved
22
.  Polyester 
polymers are synthesized from the ring opening reactions of their respective cyclic ester 
monomers
22
.  These polymers undergo bulk hydrolytic degradation
22,23
.  As these 
polymers have varying glass transition temperatures (Tg) and half-lives, they can be 
blended to produce polymers with different mechanical properties and degradation times.  
These mechanical properties can be in the range of trabecular bone
22,23
.  These properties 
allow them to be suitable for applications such as bioresorbable screws, pins, and suture 
anchors.  There are numerous other biodegradable polymers that are used as 
biomaterials
24
 , but they mostly require external fixation if needed for load bearing 
applications.  Furthermore, the bulk degradation that these polymers undergo can make it 
difficult to tune appropriate degradation rates.  Rapidly degrading implants have been 
known to produce sinuses filled with fluid
25
.  More slowly degrading amorphous 
polymeric implants can lead to crystallites that cause an inflammatory response
25
 due to 
the small size of remnants
26
.      
 Ceramics 
  As inorganic phase of bone provides the hardness of bone, ceramics are 
synthesized from inorganic, nonmetallic materials.  Ceramics are attractive due to their 
high compressive strength.  Calcium-based ceramics such as hydroxyapatite (HA) and 
tricalcium phosphate (TCP) are popular as it is possible to incorporate interconnected 
pores within the implant.  Porous HA can created by several processes such as  
hydrothermal exchange of bone or naturally occurring coralline apatite 
2728
, while TCP is 
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made by homogenizing TCP powder with naphthalene
18,27
.  HA is typically stronger than 
TCP; however, TCP  is more soluble and readily to undergo biologic degradation
18
.  HA 
and TCP have been shown to be effective in bridging long bone defect in animal 
models
27
, but HA systems have been shown to slowly remodel in cancellous sites
18
.  In 
contrast, TCP has exhibited rapid dissolution and resorption leading to poor structural 
properties
18
.  The ions released from the dissolution of TCP can support osteoblastic bone 
formation, but can also cause systemic risk
27,29,30
.   
Calcium bone cements have been used for fracture augmentation in the hip, distal 
radius, and vertebral body 
18,29
.  Norian, one of several manufactured calcium phosphate 
cements, produces an injectable paste comprising of calcium phosphate cement which 
contains monocalcium phosphate, tricalcium phosphate, calcium carbonate, and a sodium 
phosphate solution 
18,29
.  Like HA and TCP, calcium phosphate cements can be brittle and 
have the potential to cause serious inflammatory reactions due to free ions in the mineral 
matrix
29
.  Bioactive glass, which contains various oxides, has the ability to strongly bind 
with bone tissue
8
.  Like calcium phosphates, bioactive glass can have strengths 
comparable to cortical bone
8
.  However, bioactive glass is also reported to be brittle and 
often hard to machine for bone defects that are irregular in shape [4].   
Composites 
Integrating multiple biomaterials into one composite material utilizes the 
advantages of each constituent, while eliminating the potential disadvantages.  Various 
fillers have been used in conjunction with polymeric technologies to form composites.  
Materials such as hydroxyapatite (HA) have been used as resorbable fillers.  Composite 
intramedullary (IM) rods have been synthesized from HA and polylactide using 
11 
 
compression molding 
31,32
.  These IM rods ranged from 20-30% HA and exhibited 
bending strength and modulus up to 280 MPa and 7.8 GPa, respectively.  Resorption and 
remodeling of new bone was observed after 5-7 years in a NZW rabbit femoral defect 
model.  The results from this study indicate that polymer-based composites can meet both 
mechanical and biological targets.  Bioactive glass/poly(-caprolactone-co-D,L-lactide) 
composites have been show to be injectable at a temperature range of 47-50 ˚C, which is 
not an ideal range.  These injectable composites exhibit compressive strengths of 7.7 
MPa and a Young‟s modulus of 153 MPa 33.  Young‟s modulus values as high as 13.6 
GPa have been achieved using urethane dimethacrylate, 2-hydroxylethyl methacrylate, 
and a photosynthesizing agent 
34
.   
Polyurethanes 
 
 Polyurethanes, a versatile material used for several applications, have been used 
for biomedical applications since 1960s and 1970s
35,36
.  They are a versatile group of 
materials as it has a wide range of mechanical, physical, and biological properties.  
During the synthesis of polyurethanes, a nucleophilic reaction occurs between an 
isocyanate and polyol.  In this reaction, the hydroxyl group of the polyol (nucleophile) 
reacts with the NCO group of the isocyanate (electrophile) to form a urethane bond.  
Isocyanates can react with alcohols, amines, and water.  The reaction with water forms 
carbon dioxide gas, which forms pores throughout the material producing a porous foam.   
12 
 
 
Figure I.3: Reaction between a polyester triol and triisocyanate that produces a 
polyurethane. 
 
 Isocyanates can be either aromatic or aliphatic.  Although aromatic isocyanates 
are more active than allophatic isocyanates, aromatics are typically more toxic 
36
.  
Normally, isocyanates are prepared as prepolymers or quasi-prepolymers prior to 
polyurethane synthesis.  Prepolymers and quasi-prepolymers typically have a free NCO, 
unreacted isocyanate end groups,  content of 1 to 15 wt%  and 16 to 32 wt%, respectively 
36
.  These prepolymers are believed to enhance the mixing between the polyol and 
isocyanate phases
36
.  Polyols, which can have a range of molecular weights, are 
synthesized using a starter molecule.  The number of reactive hydroxyl groups on its ends 
is defined as its functionality.  The ratio of monomer to starter controls the molecular 
weight of the polyol.   
 Polyurethane systems can be cast into various shapes using a reactive liquid 
molding process.  In this process, the resin component (isocyanate or prepolymer) is 
mixed with the hardener component (polyol and catalyst).  The hardener component can 
13 
 
also include fillers, water, and surfactants.  The polyurethane index is the ratio of NCO 
equivalents to hydroxyl equivalents multiplied by 100.  The equivalent weigh is the 
weight of the functional groups.  Typically, the index for polyurethanes vary from 100 to 
125
36
.     
 The characterization of polyester-urethanes has been widely studied
35,36
.  These 
polyurethanes degrade hydrolytically, but the presence of enzymes in the physiological 
environment can also contribute to degradation
35
.  Microphase separation is common as 
the polyol component, which creates a soft segment with a typical has a melting point of 
less than 30 °C
35,36
.   In contrast, the hard segment (isocyanate), has a melting point of 
greater than 100 °C.  As soft segments have mobility, polyurethanes have the capacity to 
adapt to their environment with hard segments being polar and soft segments being non-
polar
35
.   
Research Objective 
 
In this research, a polyurethane composite system based from lysine-derived 
isocyanates, polyester polyols, and fillers was studied as a family of novel biomaterials 
for bone tissue engineering. As this is a versatile system, it is desirable that these 
materials span a wide range of mechanical properties and physical structures to support 
various bone tissue engineering applications. The PUR composite system should be both 
implantable and injectable.  Furthermore, the PUR composite system should be both 
osteoconductive and osteoinductive.   
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To achieve these objectives the following approach was taken: 
-Synthesis, characterization, and remodeling of calcium phosphate (CaP)/PUR implants 
(Chapter 2) 
- Remodeling of AMBP/PUR implants in a rabbit distal femur model (Chapter 3) 
-Synthesis, characterization, and remodeling of porous AMBP/PUR BVF in a rabbit 
calvarium model (Chapter 4) 
-Remodeling of AMBP/PUR BVF with rhBMP-2 in a rabbit calvarium model (Chapter 5) 
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CHAPTER II.  
Synthesis, characterization, and remodeling of calcium phosphate (CaP)/PUR 
implants 
 
 
Introduction 
 
 Calcium phosphates (CaP) have been extensively investigated for treating osseous 
defects. Hydroxyapatite (HA) and tricalcium phosphate (TCP) have been shown to be 
osteoconductive 
1
.  Bone comprises approximately 70% mineral content, which is 
primarily HA 
2
.  Thus because of its natural presence in bone, synthetic HA is an 
attractive bone substitute.  HA is prepared from the hydrothermal conversion of bone or 
naturally occurring coralline apatite, and it can be synthesized with variable porosity 
3
.  
TCP is a biocompatible and bioactive ceramic that has been demonstrated to bond to 
bone directly 
4,5
.  While HA bone cements exhibit compressive strengths in the range of 
4-50 MPa 
6,7
,  TCP has a significantly lower strength than HA 
3
.  Despite their favorable 
biocompatibility and osteoconductivity, both HA and TCP are subject to brittle fracture 
and graft migration, potentially requiring additional surgeries for repair or removal 
3,8,9
.   
 CaP/polymer composites have been synthesized to reduce the brittleness of CaP 
as well as increase the bioactivity of the polymer 
8
.  Multiple polymeric systems have 
been used to prepare CaP composites with varying porosities and compositions 
10
.  
HA/chitosan/PLA composites synthesized using in situ precipitation with 50-80 wt% HA 
exhibited compressive elastic modulus and strength values in the range of 416-857 MPa 
and 166-256 MPa, respectively 
11
.  HA/PLA composites synthesized using solvent 
19 
 
casting at lower HA contents (30-40 wt%) had a bending strength and modulus as high as 
269 MPA and 7.6 GPa, respectively 
12-15
.  These composites remodeled almost 
completely when implanted in rabbit distal femurs after 5-7 years 
12
.     
 Two-component biodegradable polyurethanes (PUR) offer several advantages in 
the synthesis of CaP composites.  PUR systems based on lysine polyisocyanates are 
biocompatible and degrade to non-toxic breakdown products 
16-21
.  Furthermore, they 
comprise a reactive system that is suitable for injectable applications 
20,22
.  TCP/PUR 
composites (10 wt% -TCP) prepared from lysine ethyl ester diisocyanate (ELDI) 
exhibited compressive modulus and strength of 2.3 GPa and 139 MPa, respectively 
21
, 
and supported appositional bone growth and remodeling when injected into femoral 
cortical defects in sheep 
22
. PUR chemistry also enables interfacial binding between the 
polymer and filler phases, as we have shown in composites prepared from lysine 
triisocyanate (LTI) and allograft bone particles 
19
.  While CaP/polymer composites 
incorporating relatively low volume fractions of CaP support cellular infiltration and new 
bone formation, remodeling of these materials proceeds slowly (e.g., 5 – 7 years for 
complete remodeling).  In contrast, PUR composites utilizing mineralized allograft bone 
particles at concentrations above the random close packing (RCP) limit of 64 vol% 
supported rapid (e.g., 6 weeks) infiltration and remodeling by providing a pathway for 
cellular infiltration as osteoclasts resorb the filler phase 
19
.  In the present study, we 
fabricated CaP/PUR composites with the CaP filler content exceeding the RCP limit to 
promote cellular infiltration and remodeling.  PUR composites were synthesized from 
both HA and -TCP to investigate the mechanical properties, in vitro cellular response, 
and in vivo bioactivity when implanted in femoral defects in rats.   
20 
 
Materials and Methods 
 
Materials 
Lysine triisocyanate (LTI) was purchased from Kyowa Hakko (New York, NY). 
Tegoamin 33, a tertiary amine catalyst, was received from Goldschmidt (Hopewell, VA).  
Glycerol, stannous octoate, and -caprolactone were purchased from Sigma-Aldrich (St 
Louis, MO), and glycolide and DL-lactide were supplied by Polysciences (Warrington, 
PA).  Hydroxyapatite (HA) (50-150 m) and tri-calcium phosphate (TCP) (100-300 m) 
were purchased from Berkley Biomaterials.   
Fabrication of CaP/PUR Composites 
A polyester polyol (600 MW) with a backbone of 60% caprolactone, 30% 
glycolide, and 10% lactide was synthesized using known methods.  The components of 
the composite were mixed using a one-shot method, wherein the appropriate amounts of 
Tegoamin 33, polyester triol, CaP, and LTI were added to a 10 mL cup and mixed using a 
Hauschild SpeedMixer (FlackTek, Inc., Landrum, SC).  The mixture speed was gradually 
ramped to 3300 rpm for one minute and mixing continued at 3300 rpm for 30s.  The 
composites incorporated 79.0 wt% (66.2 vol%) CaP; composites incorporating 70.0 wt% 
(56.8 vol%) CaP were used in biomechanical testing for comparison. The reactive paste 
was transferred to a cylindrical mold, compressed to approximately 63,000 lbf for 50 
minutes, de-molded to yield a green cylinder (6.1 mm diameter), and cured at 37˚C for 
twelve hours in a vacuum oven.  The four formulations listed in Table 2.1 were 
synthesized to study mechanical properties, cellular infiltration, and remodeling in a rat 
femoral plug model. 
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Table II.1: CaP treatment groups. 
 
Treatment Filler Filler 
wt% 
HA70 hydroxyapatite 70 
HA79 hydroxyapatite 79 
TCP70 tricalcium 
phosphate 
70 
TCP79 tricalcium 
phosphate 
79 
 
Mechanical properties, Scanning electron microscopy, in vitro degradation 
Cylindrical PUR/AMBP rods, approximately 6.3 x 12.6 mm (n = 3), were 
fabricated by compression molding.  The rods were hydrated in PBS 24 hours prior to 
testing.  The cylinders were placed between two fixed compression platens of an MTS 
898 equipped with a 13 kN load cell, pre-loaded to approximately 12 N, and loaded at 24 
mm min-1 until failure.  Significant differences between treatement groups were 
determined by one-way ANOVA with bonferroni correction (p<0.05). Sample 
composites (approximately 5 mg) were mounted on a SEM pin stub mount and sputter-
coated for 60 seconds using a Cressington Q108 sputter coater, which deposited gold at a 
30 mA current.  A Hitachi S-4200 scanning electron microscope was used to acquire 
images at a voltage of 10 kV. 
The in vitro degradation rates of CaP/PUR composites were evaluated by 
measuring the mass loss at various time points up to 7 weeks of incubation of 10-mg 
samples (n=5) in 1 ml phosphate buffered saline (PBS; pH 7.4) at 37°C. At each time 
point, the samples were rinsed in deionized water, dried under vacuum for 48 h at room 
temperature, and weighed. 
22 
 
In vitro cell proliferation on CaP/PUR composites 
 Discs of approximately 250 m in thickness were used for cell culture studies.  
The discs were cleaned and sterilized by sonicating in both deionized (DI) water and 
ethanol.  Prior to seeding 2T3 cells (a clonal osteoblast cell line), the discs were washed 
with additional DI water and conditioned in incomplete alpha minimum essential media 
(-MEM, Fisher Scientific).  A cell number of 5 x 103 was seeded on each composite in 
12-well tissue-culture polystyrene plates.  Cells were cultured with -MEM containing 
10% fetal bovine serum (FBS, HyClone), and 1% penicillin/streptomycin (HyClone) at 
37 ºC in a humidified incubator supplemented with 5% CO2. The medium was changed 
every 2 days.   
After 2 and 5 days, cell proliferation on CaP/PUR composites was evaluated.  The 
cell-seeded scaffolds were washed with PBS, and 4 M Calcein AM (Live/Dead 
Viability/Cytotoxicity Kit, Invitrogen-Molecular Probes) was added to the samples.  
Calcein AM dye is retained within live cells, imparting green fluorescence 
(excitation/emission: 495/515 nm). Cell proliferation was assessed qualitatively by 
fluorescent images acquired with an Olympus DP71 camera attached to a fluorescent 
microscope (Olympus CKX41, U-RFLT50). Osteoblastic cell proliferation on CaP/PUR 
composites was quantitatively evaluated using PicoGreen assays (n=4). After the cells 
were removed from the discs using 0.25% trypsin and 1 mM ethylenediaminetetraacetic 
acid (EDTA, Invitrogen), DNA content was measured using the Quant-iT PicoGreen 
dsDNA Assay kit (Invitrogen-Molecular Probes) according to the manufacturer's 
instructions. Fluorescence intensity was measured at excitation and emission wavelengths 
of 495 and 515 nm. Student‟s t test was performed for statistical comparison (p<0.05). 
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In vitro osteogenic differentiation on CaP/PUR composites 
In vitro osteogenic differentiation of 2T3 cells cultured on CaP/PUR composites 
was evaluated (n=4). A cell number of 5 x 10
4
 was seeded on CaP/PUR composites. 
After confluence, the cell-seeded scaffolds were cultured with osteogenic medium 
containing 2.5% FBS, 10 mM β-glycerophosphate (Sigma-Aldrich), and 100 μg/ml 
ascorbic acid phosphate (Wako, Osaka, Japan) for 7 days.  The cells were removed from 
the CaP/PUR discs, washed with PBS and lysed with 0.1% Triton X-100. The cells were 
then subjected to three freeze/thaw cycles. The lysates (20l) were added to 100l of 
substrate buffer (2 mg/ml disodium p-nitrophenylphosphate hexahydrate and 0.75M 2-
amino-2-methyl-1-propanol). After incubation of the mixtures at 37°C for 30 min, 
absorbance at 405 nm was measured. Alkaline phosphatase (ALP) activity was 
determined from a standard curve generated by employing the reaction of a p-nitrophenyl 
solution. The ALP activity was normalized by the total protein content determined using 
the BCA assay (Pierce). Student‟s t test was performed for statistical comparison 
(p<0.05). 
In Vivo Rat Study 
All surgical procedures were reviewed and approved by the Institutional Animal 
Care and Use Committee. Male Sprague–Dawley rats (Harlan Labs) aged 8 weeks (200–
250 g) were used for this study. A monocortical plug bone defect with a diameter of 3mm 
was created in the distal region of the femur diaphysis, and a cylindrical CaP/PUR 
composite (3 x 5 mm) was implanted into the defect.  After 4 weeks, the rats were 
sacrificed and the femurs removed and fixed in 10% phosphate-buffered formalin. 
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X-ray and CT Analysis 
  Radiological analysis of the defect in the distal femur at week4 was performed 
using a Faxitron LX-60 x-ray system (Faxitron, 40kV at 8 s exposure time).  Micro CT 
analysis was also performed using Scanco CT40 (SCANCO Medical) at a voxel size of 
24 m. The X-ray source settings were 55 kVp and 145 mA with an integration time of 
300 ms. 
Histology 
Rat bones were decalcified with 10% EDTA, dehydrated, embedded in paraffin, 
and sectioned at 5 m thickness. The coronal slice sections were stained with 
hematoxylin and eosin (H&E). Specimens were examined under light microscopy.  
Tartrate resistant acid phosphastase (TRAP) staining was used to confirm the presence of 
osteoclasts.   
Results  
 
Mechanical properties, Particle size, In vitro degradation 
 Figure 2.1 summarizes the compressive modulus and strength values for the 
CaP/PUR composites, which ranged from 2.5-3.6 GPa and 59.6-87.0 MPa, respectively.  
HA/PUR composites exhibited significantly greater compressive modulus and strength 
than the TCP/PUR composites at both filler contents. However, the volume fraction of 
filler had no significant effect on compressive strength for either type of filler.  Increasing 
the filler content for the -TCP groups had no significant effect on the modulus unlike 
the effects seen for the HA group, where the modulus increased with filler content.   
25 
 
 
Figure II.1: Compressive properties of PUR/HA and PUR/TCP composites. 
HA70: 70 wt% HA, HA79: 79 wt% HA, TCP70: 70 wt% TCP, TCP79: 79 wt% TCP. 
 
 SEM images of the HA/PUR composites are shown in Figure 2.2. After 
compression molding, the particle size was reduced from 50 – 150 m to <10 m. Higher 
magnification views of the HAPUR (79 wt%) material reveal a large number of particles 
smaller than 1 m (Figure 2.2B).  These observations suggest that the process of 
compression molding resulted in attrition of the CaP particles and accompanied by a 
significant reduction in size . 
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Figure II.2A: SEM images of HA70, HA79, TCP70, and TCP70 composites.  
 
 
Figure 2.2B. Higher magnification images of the HA79 composites. 
 
The degradation rates of the CaP/PUR composites are shown in Fig. 2.3. The 
composites showed a linear mass loss with time. In vitro degradation rates of the 
materials were relatively slow, as evidenced by the fact that both materials retained 85–
95% of their original mass after 7 weeks.   
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Figure II.3: In vitro degradation of PUR/HA and PUR/TCP composites. 
 
In vitro cell proliferation on CaP/PUR composites 
Calcein staining (Figure 2.4) showed favorable cell growth on the surface of 
CaP/PUR composites (79 wt%).  The density of live cells at day 5 increase relative to day 
2 on both HA/PUR and TCP/PUR composites. This finding suggests the biocompatibility 
of CaP/PUR composites.  Quantitative analysis by PicoGreen assay also showed that 
DNA amount of the cells significantly increased at day 5 on both HA/PUR and TCP/PUR 
composites (Figure 2.5).  The rate of proliferation on the TCP/PUR composites was 
greater than the rate of cell growth on HA/PUR composites.   
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Figure II.4: Proliferation of 2T3 cells seeded on the surface of PUR/HA and PUR/TCP 
composites. 
The cells were stained by calcein at day 2 and day 5. The bars: 250 m. 
 
 
Figure II.5: DNA amount of 2T3 cells cultured on PUR/HA and PUR/TCP composites 
surfaces. 
Time points: day 2 and day 5. *: p<0.05. 
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In vitro osteogenic differentiation on CaP/PUR composites 
ALP activity of the cells seeded on CaP/PUR composites significantly increased 
when cultured with osteogenic medium (Figure 2.6), suggesting that the cells can 
differentiate on the surface of the composites. There was no significant difference in ALP 
activity between HA/PUR and TCP/PUR composites.  
 
Figure II.6: Osteogenic differentiation of 2T3 cells seeded on PUR/HA and PUR/TCP 
composites. 
ALP activity was measured at day7 after culture on the composites with osteogenic 
supplement (OS). Cont: culture without OS. *: p<0.05. 
 
X-ray and CT Analysis 
 X-rays from the extracted femurs at week4 (Figure 2.7) showed new bone 
formation around both HA/PUR and TCP/PUR composites.  Similar observations were 
made from the CT images (Figure 2.8).  The material shape became irregular at the 
boundary between the implant and newly formed bone on CT images.  These findings 
show that the composites are osteoconductive and support appositional bone growth. 
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Figure II.7: X-rays of PUR/HA and PUR/TCP composites at week 4 after implantation 
in the distal femur of Sprague-Dawley rats. 
 
 
 
Figure II.8: Micro CT of PUR/HA and PUR/TCP composites at week4. 
(A: Coronal view. B: Axial view. Scale bars: 500 m.) 
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Histology 
 Histological sections of the implanted CaP/PUR composites (Figure 2.9) showed 
extensive bone matrix formation at the surface of both HA/PUR and TCP/PUR 
composites, which is consistent with the radiographs and CT images. Higher 
magnification images revealed cellular infiltration into the materials. No inflammatory 
response was observed at week 4. As observed in Figure 2.9A, the HA/PUR composites 
showed evidence of limited remodeling near the base of the implant.  However, there 
appeared to be a minimal change in the size of the original implants for both treatment 
groups, suggesting that the extent of cellular infiltration and remodeling in the 
composites was low.  Histological sections stained for TRAP (Figure 2.10) showed 
osteoclast resorption at the boundary between the implants and newly formed bone.   
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Figure II.9: Histological pictures (HE staining) of PUR/HA and PUR/TCP composites at 
week 4. 
(A: P- proximal, D- distal, I- implants. The bars: 500m. B: High magnification. The 
white arrows: cell infiltration to the scaffolds. The black arrows: New bone formation. 
Scale bars: 100m.) 
 
Figure II.10: Histological pictures (TRAP staining) of PUR/HA and PUR/TCP 
composites at week 4. 
(I: implants, NB: New bone formation, The black arrows: TRAP positive multi-nucleated 
cells. Scale bars: 100 m.) 
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Discussion  
 
 Multiple CaP/polymer composites with varying porosities and filler contents have 
been studied as biomaterials 
10
.  These systems typically incorporate filler contents far 
below the random closed packing limit (RCP) of spheres (~64 vol%) 
23
, and 
TCP/polymer composites have been reported to decrease in strength as the amount of 
TCP increases 10. However, another study has shown that varying the filler content of 
HA/chitosan (CS) composites has a minimal effect on the strength of the overall 
composite at values under 80 wt% (~64 vol%) 
11,23
. Similarly, varying the filler content 
from 70 to 79 wt% (56.8 to 66.2 vol%) for the CaP/PUR composites in this study had no 
significant effect on strength. As expected, HA/PUR composites exhibited superior 
compressive modulus and strengths compared with the TCP/PUR composites. At the 
70 wt% filler content, there were no significant differences in the compressive modulus 
in the treatment groups.  However, once the filler content was increased to 79 wt%, there 
was a significant difference suggesting a greater contribution of the filler composition at 
the higher loading. The strength of the HA/PUR composites (87.0 MPa) was lower than 
values reported for chitosan (CS)/HA composites, which were also prepared at 80 wt% 
HA (166 MPa) 
11
.  However, the compressive modulus of HA/PUR composite materials 
(4.3 GPa) was an order of magnitude higher than that of the CS/HA composites (416 
MPa). 
   The in vitro degradation rate of CaP/polymer composites varies substantially 
depending on the polymers and ceramic components, as well as the manufacturing 
methods  
24-26
.  Generally, the composites degraded more slowly and maintained their 
shape longer than the pure polymer 
27
.  The CaP/PUR composites in this study also 
34 
 
degraded slowly in vitro, with degradation rates in PBS ranging from 0.8 – 2.0 
wt%/week.  While TCP is more water-soluble than HA 
28,29
, HA/PUR degraded relatively 
faster than TCP/PUR in this study. High HA content may influence the pH of the 
surrounding microenvironment  
30
, which can influence the polymer degradation rate 
31
. 
 Cellular proliferation was higher on the surface of the TCP composites.   
Previous studies have suggested that -TCP can enhance osteoblast viability and 
proliferation, as calcium and phosphate ions stimulate osteoblastic activity 
3,21,32
.  In 
contrast, the dissolution of crystalline HA is slow and reduces the pH of the surrounding 
microenvironment, thereby slowing cell growth 
30
.  Similarly, in the present study the -
TCP/PUR composites supported significantly higher proliferation of osteoprogenitor cells 
compared to the HA/PUR composites, which is conjectured to result from the dissolution 
of -TCP particles exposed on the surface of the composites.  Interestingly, the filler type 
had no effect on ALP activity of the cells.   
 Remodeling of CaP/polymer composites in vivo has been observed in several 
studies.  HA/PLLA composites implanted in rabbit femoral plug defects have taken up to 
7 years to remodel 
12
. In the present study, both radiographs and histological sections 
show appositional bone growth at the surface the CaP/PUR composites, which has also 
been observed for allograft/PUR composites implanted in the rabbit distal femur 
19
.  
However, in the present study there was less resorption and cellular infiltration observed 
for the CaP/PUR composites compared to the allograft/PUR composites.    Osteoclasts 
infiltrated and resorbed the CaP/PUR composites near the bone-implant interface, as 
confirmed by TRAP staining. While there is limited evidence of remodeling at the early 
time point (4 weeks) investigated, infiltration of osteoclasts near the implant-bone 
35 
 
interface suggests that at later time points the CaP/PUR composites may remodel via 
slow reverse creeping substitution 
33-35
, as reported previously for allograft/PUR 
composites. However, the rates of cellular infiltration and resorption were substantially 
less than those observed for allograft/PUR composites at similar filler loadings 
19
. The 
SEM images (Figure 2.2) indicate that the CaP particles were fractured due to the 
compression molding process, which reduced the size of many of the particles to <10 m.  
In contrast, these results were not observed for compression-molded allograft 
bone/polymer composites.
19
  The size of allograft bone particles dramatically affects the 
potential of the particles to remodel, which is highest for particles ranging from 90-300 
m 36, and particles < 100 m are only slowly resorbed. Thus the relatively slow 
osteoclast-mediated resorption of the CaP composites is likely due, at least in part, to the 
small size of the particles. Alternatively, previous studies have suggested that cortical 
allograft bone particles are more rapidly resorbed and replaced by living bone in the 
rabbit distal femur than HA particles due to the organic components in the allograft bone 
37
. Allograft bone particles, which have been reported to undergo up to 70% resorption by 
osteoclasts after 14 days
38
, resorb faster than HA particles (0.02 m3 m-2 day-1)39 in 
vitro. These observations suggest that the slower resorption rate of CaP composites could 
also be attributed to the differences in composition between CaP and allograft. 
 In this study, we examined the in vivo bioactivity of CaP/PUR composites using a 
rat femoral plug defect model with a short-term observation period.  Large animal models 
with a long-term observation may be required in the future to further investigate the 
osteoconductive ability and full remodeling of the materials.  However, the data from this 
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study suggest the potential of CaP/PUR composites for weight-bearing implants as a 
biocompatible, osteoconductive, and resorbable material. 
Conclusions 
 
 CaP/PUR composites have been synthesized using a two-component polyurethane 
derived from LTI.  The mechanical properties of the composites suggest that they could 
be useful for weight-bearing applications as the PUR increased the compressive strength 
of the CaP.  Cell culture studies showed that CaP/PUR composites are biocompatible, 
with -TCP further enhancing cell viability and proliferation.  CaP/PUR composites also 
supported the differentiation of 2T3 cells into osteoblasts.  When implanted in the distal 
femurs of rats, CaP/PUR composites were shown to be biocompatible and 
osteoconductive with no adverse responses observed. Histological sections revealed 
evidence of infiltration of osteoclasts and resorption of CaP near the bone-implant 
interface, as well as appositional remodeling via slow reverse creeping subsitution.  The 
current study suggests that CaP/PUR composites could be a potentially useful option for 
weight-bearing implants. 
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CHAPTER III.  
Synthesis, characterization and remodeling of allograft mineralized bone 
particle/polyurethane implants in a rabbit distal femur model 
 
Introduction 
 
There are numerous biomaterials available to treat orthopaedic defects, however each 
of these platforms has limitations especially for weight-bearing applications.  Several 
design parameters that must be considered during the development of weight-bearing 
biomaterials for bone tissue engineering such as porosity, mechanical strength, and 
degradation profile. Resorbable polymers have been extensively investigated for bone 
repair
1,2
. Ideally, scaffolds prepared from resorbable polymers should support cell 
attachment and ingrowth of new tissue, as well as biodegrade at a rate matching that of 
new tissue ingrowth.  Fabrication of scaffolds with interconnected pores has long been 
considered a prerequisite for integration of bone within a polymer.
3,4
 However, pores 
significantly diminish the initial mechanical properties
4
 of the materials, thus rendering 
them largely unsuitable as load-bearing devices 
5
.  
Biomedical devices based on poly(methyl methacrylate) (PMMA), such as hard-
tissue replacement (HTR) implants
6
, are used clinically to restore form and/or 
functionality.  However, these biomaterials neither remodel nor integrate with host tissue 
and have a number of drawbacks, including toxicity of the monomer
7
 and potential bone 
necrosis due to the exothermic reaction.
8,9
 Furthermore, PMMA is not resorbable and can 
induce an inflammatory response.
10-13
 Due to these undesirable properties, resorbable 
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alternatives to PMMA are have been developed, such as injectable calcium phosphate 
(CaP) bone cements. These materials cure endothermically at 37ºC
14
 and are resorbable 
and osteoconductive
15-18
, but in many cases, the degradation rate does not match that of 
new bone formation.
19,20
 Furthermore, the rate of resorption is slow due to the small pore 
size.
21,22
  Thus, despite substantial progress toward the design of therapeutics for healing 
bone, there remains a need for biomaterials that exhibit mechanical properties 
comparable to those of the host bone and that actively participate in the healing process, 
resulting in integration with recipient bone and remodeling with ultimate replacement by 
host tissue. 
Ceramics, such as calcium phosphates, have been widely investigated as synthetic 
bone graft materials due to their bioactivity and biocompatibility. These biomaterials 
degrade in vivo by dissolution and osteoclastic resorption.
1
  Resorbable polymer/ceramic 
composites have been investigated as weight-bearing implants that integrate with host 
bone.
23-26
 Intramedullary (IM) rods fabricated from composites incorporating 30–40 wt% 
hydroxyapatite (HA) and 60–70 wt% poly(L-lactide) (PLLA) had bending strengths 
ranging from 260 – 280 MPa and moduli ranging from 7.6 – 9.8 GPa, which is a 
substantial improvement on the reportedly low bending and shear strengths of calcium 
phosphates.
27,28
  When implanted in the distal femur of rabbits, the composites partially 
remodeled and integrated with host tissue after 4 years. The resorption and remodeling 
process was slow. After 4 years, the cross sectional area decreased 4 – 68%, and the 
extent of bony ingrowth varied from 18 – 30%.26   
Both autograft and allograft bone have been extensively investigated in bone 
tissue engineering.
29-31
 With the advent of new technologies for sterilization and viral 
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inactivation, mineralized human bone allografts have emerged as a preferred implant type 
for weight-bearing orthopaedic and spinal applications.
32
 Autograft is highly effective, 
but requires a second surgical site with additional morbidity.  Osteogenic cells present in 
the autologous bone are a major contributor to its effectiveness
33
, so these materials must 
be implanted at the time of harvesting.  Allografts have excellent biomechanical 
properties and they undergo extensive osseous integration. However, the anatomy of the 
donor bone limits the reproducibility and range of mineralized allograft shapes available 
for clinical use.
32
 Furthermore, while the extent of integration is generally considered 
adequate, remodeling of the graft seldom exceeds 50%, which limits their use clinically.
34
 
Since remodeling proceeds from the external surface to the interior by the process of 
creeping substitution
18,33,35
, the limited remodeling of allograft devices is likely due to 
their low specific surface area, which scales inversely with particle diameter. By 
processing the allograft cortical bone into small mineralized bone particles (AMBP, ~100 
- 600 m), the specific surface area is increased.  The remodeling potential of materials 
incorporating particulated allograft was examined in a study wherein compression-
molded composites comprising rabbit allograft mineralized bone particles (AMBP) (60-
75 wt%) and poly(lactide-co-glycolide) (PLGA, 25-40 wt%) were implanted in bilateral 
unicortical plug defects in the distal femurs of adult NZW rabbits.
36
 Histological sections 
as early as 4 weeks showed regions of cellular penetration, active bone-formation, and 
newly formed bone, which were most extensive at 75 wt% (~61 vol%) AMBP. The 
dramatically higher rate of remodeling of the AMBP composites (~4 – 6 weeks) relative 
to the HA/PLLA implants (~4 – 5 years) was attributed to either the greater bioactivity of 
AMBP or the higher volume fraction at which it was present in the composite.
36
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 Although previous studies have shown that composites with poly(-ester) binders 
(e.g., PLGA and PLLA) remodel in rabbit models of bone healing, thermoplastic 
polymers cannot be injected and strategies for improving interfacial bonding are limited.  
To address these limitations, in this study we have investigated reactive two-component 
biodegradable polyurethane (PUR) networks as the polymer binder.  Biodegradable 
polyurethanes support new bone ingrowth in vivo and biodegrade to non-cytotoxic 
decomposition products
37-44
, and the mechanical properties and degradation rate can be 
controlled through the choice of intermediates.
43,45,46
  Furthermore, polyurethanes can be 
processed by two-component reactive liquid molding
43,46-50
, thus making them suitable 
for injectable applications such as bone cements and void fillers. It was reasoned that the 
polymer would covalently bind to the allograft bone filler through the reaction of 
isocyanate (NCO) groups with the collagen present in the bone particles.  In addition, it 
was hypothesized that surface-demineralization
51
 ,the process of acid etching to expose 
collagen fibrils, of the AMBP would enhance surface binding through exposure of 
collagen fibrils. Strong bonding between the polymer and filler phases is known to 
increase the mechanical strength of the composite.
52-54
 Also, several studies have 
suggested that the presence of a collagen layer, specifically the P-15 peptide, on the 
surface of substrates enhances the attachment of osteoblast-like cells
55-57
, which may 
provide added benefits of surface demineralization. In this study, we have investigated 
the effects of surface-demineralization and polymer composition on mechanical 
properties, cellular infiltration, and new bone formation in a unicortical plug defect model 
in NZW rabbits. 
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Materials and Methods  
 
Materials 
Lysine triisocyanate (LTI) was purchased from Kyowa Hakko (New York, NY). 
Tegoamin 33, a tertiary amine catalyst, was received from Goldschmidt (Hopewell, VA).  
Glycerol, stannous octoate, and -caprolactone were purchased from Sigma-Aldrich (St 
Louis, MO), and glycolide and DL-lactide were supplied by Polysciences (Warrington, 
PA).  Rabbit allograft mineralized bone particles (AMBP, 481 m mean particle size) 
were received as a gift from Osteotech, Inc. (Eatontown, NJ). 
Synthesis of polyester triols 
Polyester triols were synthesized using published techniques.
46,58
  Briefly, the 
appropriate amounts of glycerol starter and -caprolactone, glycolide, and DL-lactide 
monomers were mixed under argon at 140
o
C for 30h.  When the reaction was complete, 
the polyester triol was cooled, washed with hexane, and dried at 80
o
C under vacuum.  
The backbone of the polyester triols comprised 60% -caprolactone, 30% glycolide, and 
10% DL-lactide (6C3G1L).  Molecular weights of 300 g/mol (6C3G1L300) and 600 
g/mol (6C3G1L600) were synthesized for this study.   
Preparation of surface-demineralized  bone particles (SDBP) 
Surface demineralized bone particles (SDBP) were prepared using published 
methods.
59
  AMBP was sonicated  in 0.1 M hydrochloric acid for 2.5 minutes followed 
by saturation in 2.5% trypsin at 37˚C  overnight.  Sonication in hydrochloric acid was 
repeated for the same time period followed by 48 hours of saturation in 2.5% trypsin.  
The resulting SDBP was rinsed thoroughly with DI water and lyophilized for 48 hours.  
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Characterization of reactivity of allograft bone particles by FITC labeling.  
 Approximately 10 mg of rabbit AMBP or SDBP was added to 2 mL centrifuge 
tubes along with 1 mL of borate buffer.  A solution of FITC, in borate buffer, was 
prepared to yield a concentration of 7 mg/mL, and 0.1 mL of the resulting solution was 
added to each tube.  As a control, only borate buffer was added to three of the AMBP 
samples.  The tubes were placed on a hematology mixer for 1 hour.  The tubes were 
centrifuged at 2500 rpm for 3 minutes to remove excess FITC from each tube, and the 
AMBP was washed thrice with borate buffer solution.  The AMBP was transferred to a 
96 well plate by suspending it in a solution of 0.1 mL of borate buffer.  The fluorescence 
of each well was read using a FL600 microplate reader at an excitation of 495 nm and an 
emission at 525 nm.  The fluorescence was read at a sensitivity of 75.  
Scanning Electron Microscopy 
Rabbit AMBP (approximately 5 mg) was mounted on a SEM pin stub mount and 
sputter-coated for 60 seconds using a Cressington Q108 sputter coater, which deposited 
gold at a 30 mA current.  A Hitachi S-4200 scanning electron microscope was used to 
acquire images at a voltage of 1 kV.    
Fabrication of AMBP/PUR composites 
The components of the composite were mixed using a one-shot method, wherein 
the appropriate amounts of Tegoamin 33, polyester triol, AMBP, and LTI were added to 
a 10 mL cup and mixed using a Hauschild SpeedMixer (FlackTek, Inc., Landrum, SC).  
The target index, the ratio of NCO groups to hydroxyl groups multiplied by 100, was 
125.  The target catalyst concentration was 5000 ppm.  The mixture speed was gradually 
ramped to 3300 rpm for one minute and mixing continued at 3300 rpm for 30s.  All 
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composites incorporated 79.0 wt% (66.2 vol%) allograft bone.  The reactive paste was 
transferred to a cylindrical mold, compressed to approximately 63,000 lbf for 50 minutes, 
de-molded to yield a green cylinder (6.1 mm diameter), and cured at 37˚C for twelve 
hours in a vacuum oven.  The four formulations listed in Table 3.1 were designed to 
investigate the effects of surface demineralization and polyester triol molecular weight on 
mechanical properties and remodeling in a rabbit distal femoral plug model.  
Infrared spectroscopy 
Potassium bromide pellets of both composites and AMBP were produced using a 
pellet die assembly.  A thin disc from the composite rods was cut using a Buehler 
diamond embedded circular saw, and approximately 8 mg of the composite and AMBP 
were ground using mortar and pestle followed by the addition of 200 mg of potassium 
bromide.  The resulting mixture was then pressed into a pellet.  A Bruker Tensor 27 FTIR 
was used to scan each sample.     
Mechanical and swelling properties  
Cylindrical PUR/AMBP rods, approximately 6.3 x 12.6 mm (n = 3), were 
fabricated by compression molding.  The rods were hydrated in PBS 24 hours prior to 
testing. The cylinders were placed between two fixed compression platens of an MTS 
898 equipped with a 13 kN load cell, pre-loaded to approximately 12 N, and subsequently 
loaded at 24 mm/min until failure. Swelling data were calculated from the dry and wet 
mass of the composites after 24h incubation time in PBS (a time-course study showed 
that the composites attained equilibrium by 24h swelling time).  One-way ANOVA with 
bonferroni correction (p<0.05) was used for evaluation of statistical significance for both 
µCT imaging and histomorphometry analysis.  
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Animal study 
Six New Zealand White (NZW) rabbits weighing between 3.8 and 4.1 kg were 
used in this study.  All surgical and care procedures were carried out under aseptic 
conditions per the approved IACUC protocol.  The AMBP/PUR composite plugs were 
gamma irradiated using a dose of approximately 25 kGY.  Glycopyrrolate was 
administered at 0.01 mg/kg IM followed by ketamine at 40 mg/kg IM.  Bilateral defects 
of approximately 6.1 mm diameter by 11 mm in depth were drilled in the metaphysis of 
the distal femurs of each rabbit. AMBP/PUR plugs from each treatment group (n = 3) 
were subsequently inserted into each defect.  Treatment groups for each composite were 
dispersed randomly among the rabbits.  The rabbits were euthanized after six weeks using 
Fatal-plus (2.2 mL/10 kg) intra-venously.  After 6 weeks‟ implantation time, the femurs 
were extracted and placed in a 1 X phosphate buffer solution for 2 hours followed by 
dehydration in a series of ethanol and fixation in 10% formalin for 3 weeks.    
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Table III.1: AMBP/PUR composite formulations. 
Composite AMBP300 SDBP300 AMBP600 SDBP600 
Polyol 6C3G1L300 6C3G1L300 6C3G1L600 6C3G1L600 
Filler MBP SDBP MBP SDBP 
 
 
Radiograph and Histological evaluation   
A Faxitron LX-60 x-ray system was used to acquire micrographs of the extracted 
femurs after the PBS wash.  Micrographs of each femur were taken at 40 kV with an 
exposure time 10 s. After fixation, the femurs were embedded in Technovit 7200 and 
200-m sections were cut from the resulting blocks using an Exakt band saw.  The 
sections were then ground and polished using an Exakt grinding system to less than 100 
m and stained with Sanderson‟s rapid bone stain counterstained with van Gieson.  Old 
allograft bone stained light brown, while new bone stained pink with dark blue osteocytes 
within the matrix.  The polymer was stained dark blue, while cells were stained light 
blue.   
Histomorphometry 
A rectangular region approximately 9.5 mm from the plug insertion point across 
the composite was selected for histomorphometry of the AMBP300 and SDBP300 
groups.  To determine the AMBP distribution, a 1.8 x 3.9 mm rectangle in the 
unremodeled core was also examined.  MetaMorph 7.1 was used to obtain 
50 
 
histomorphometry data from the histology micrographs.  Differentiation between new 
bone and cellular infiltration was accomplished using the Smart Brush tool in the 
Photoshop Elements 7.0 software.   The fractions of allograft, cellular infiltration, new 
bone, and residual polyurethane were measured in the regions of interest.  Significant 
differences between the AMBP300 and SDBP300 groups were determined by a t-test (p< 
0.05). 
Results 
 
AMBP and SDBP characterization 
The density of dry AMBP was determined at Micromeritics Analytical Services 
by helium pyconmetry to be 2.30 g cm
-3
.  As evidenced by the low magnification SEM 
images (Figures 3.1A and 3.1B), there were insignificant changes in particle size and 
shape after surface demineralization.  Laser light scattering was used to measure the 
particle size distribution, which was found to be log-normal with a mean value of 481± 7 
m (Figure 3.1F).  
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Figure III.1: Characterization of rabbit mineralized particles. 
Low magnification SEM images of (A) AMBP and (B) SDBP showing negligible 
changes in size and shape after surface deminerilzation.  High magnification SEM images 
of (C) MBP and (D) SDBP particles showing exposure of collagen fibrils on the surface 
after demineralization, (E) composition of the surface of MBP and SDBP measured by 
XPS, and (F) particle size distribution measured by laser diffraction (micrometrics). 
 
Reactivity of AMBP and SDBP particles 
The surfaces of the AMBP and SDBP particles were analyzed by XPS to 
characterize the composition.  Surface-demineralization removed a substantial amount of 
the mineral content at the surface, as evidenced by the significant decrease in Ca and P 
atomic concentrations and significant increase in C atomic concentration inferred from 
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the XPS spectra (Figure 3.1E).  The removal of the mineral content was anticipated to 
increase the reactivity of the surface by exposing a greater number of collagen fibrils at 
the surface, as shown by the high magnification SEM images in Figures 3.1C and 3.1D.  
The higher reactivity of the SDBP particles is demonstrated by the FITC assay (Figure 
3.2), where active hydrogen (e.g., hydroxyl and amine) groups present in the proteins on 
the surface of the particles react with the nucleophilic isothiocyanate group (N=C=S) in 
the FITC molecule.  As anticipated, surface demineralization significantly increased the 
FITC-related absorbance consistent with a significant increase in the number of FITC 
molecules bound to the surface of SDBP particles compared to AMBP.  The higher 
reactivity suggests a higher concentration of active hydrogen molecules on the surface of 
SDBP, which is anticipated to enhance the mechanical properties of the composite due to 
the higher degree of interfacial bonding between the allograft filler and reactive two-
component PUR binder. However, it is important to note that the fluorescence of the 
AMBP was also higher than that of the FITC-untreated control (AMBP in the absence of 
FITC) and FITC-treated control (tissue culture polystyrene well plate, which is 
anticipated to have a relatively low reactivity toward FITC).   
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Figure III.2: Results from a fluorescein isothiocyanate (FITC) assay. 
Surface demineralization enhances the reactivity of rabbit allograft bone particles. Rabbit 
MBP and SDBP were incubated in a FITC solution (7 mg ml
-
1) in 1 ml borate buffer for 
1 h. As a negative FITC-untreated control, only borate buffer was added to three of the 
MBP samples. After washing with borate buffer solution, the MBP and SDBP were 
suspended in 0.1 ml borate buffer and transferred to a 96-well plate. As a positive FITC-
treated control, the tissue culture polystyrene well plate was also  incubated in FITC 
solution. MBP in borate buffer was used as a control in this study. The fluorescence of 
each well was read using a FL600 microplate fluorescence reader at an absorption of 495 
nm and an emission at 525 nm. 
 
IR characterization 
The IR spectrum (Figure 3.3) suggests that the PUR phase cured completely, as 
evidenced by the absence of an NCO peak in the range of 2285-2250 cm
-1 46,60
.  Ester and 
urethane carbonyl stretching vibrations are observed near 1765 cm
-1 40,46
.  The peaks near 
560 and 1030 cm
-1
 correspond to the phosphate bands in hydoxyapatite that is part of the 
allograft bone matrix.
61
  Thus the IR spectra confirm that the reactive AMBP/PUR 
mixture cured at high conversion to form the expected structure.  
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Figure III.3: IR spectra of 6C3G1L600-SDBP composite (blue) and mineralized bone 
particles (red). 
The absence of a peak at 2285–2250 cm-1, marked by the black arrow, indicates that there 
is a negligible amount of free NCO. Most peaks are overlapping between the MBP/PUR 
composite and the MBP with the exception of the ester and urethane carbonyl peaks. 
 
Mechanical and swelling properties 
The values for the compressive modulus, strength, yield strain, and swelling are 
listed in Table 3.2.  The modulus and strength values of the composites ranged from 3.05 
to 6.01 GPa and 107.8 to 172.4 MPa, respectively.  The strain at yield varied from 4.56 to 
5.52% while swelling ranged from 2.54 to 2.97%.  Composites prepared from the 
6C3G1L300 polyester triol exhibited higher strengths and lower strains at yield than the 
composites based on the 6C3G1L600 triol, presumably due to the higher strength and 
crosslink density of the polymer binder. Composites failed in a diagonal fracture during 
the compression testing.  Surprisingly, surface-demineralization had no effect on the 
mechanical properties of the composite, as evidenced by the absence of statistically 
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significant differences in swelling or mechanical properties between treatment groups 
with the same molecular weight polyester triol.  
 
Table III.2: Mechanical and swelling properties of bone/polymer composites. 
Property MBP300 SDBP300 MBP600 SDBP600 
Compressive modulus, GPa 6.01  0.34 5.52  0.11 3.05  0.64 3.66  0.39 
Compressive strength, MPa 172.4  4.7 166.2  3.8 107.8  1.8 113.1  3.9 
Yield strain, % 4.56  0.21 4.80  0.15 5.52  0.57 5.77  0.25  
Swelling, % 2.54  0.28 2.97  0.27 2.89  0.35 3.33 ± 0.25 
 
Volume fraction bone 
Histological sections near the center of the implants where cells had not yet 
infiltrated are shown in Figures 3.4A and B. Histomorphometric analysis of the region of 
the implant shown in Figure 3.4C was performed to calculate the volume fractions of 
bone and polymer for each treatment group.  As shown in Figure 3.4D, the polymer 
fraction near the core ranged from 26 – 32 vol%, while the bone fraction varied from 66 – 
74 vol%. There was a significant difference in bone fraction observed between the 
6C3G1L300-AMBP and 6C3G1L600-SDBP groups. From the mass balance data, the 
volume fraction polymer ranged from 32.1 – 32.4 vol%, while the volume fraction 
allograft varied from 68.6 – 68.9 vol%, respectively. Thus the histomorphometric and 
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mass balance data are in agreement that the bone content exceeded the random close-
packed (RCP) limit of 64 vol%.  Furthermore, the micrographs in Figure 3.4A and B 
exhibit multiple contacts between adjacent bone particles. 
 
Figure III.4: Distribution of allograft bone composites. 
Allograft particles are more uniformly distributed in 300 MW composites compared to 
600 MW SDBP composites. A: 6C3G1L300-MBP, B: 6C3G1L600-SDBP, C: region of 
interest, D: Volume fractions of bone and polymer measured by histomorphometry (n = 
6) show higher variability in the center region of the implant for 600 MW SDBP 
compared to the other treatment groups with a significant difference between the 
6C3G1L300-MBP and 6C3G1L600-SDBP groups. 
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Radiograph analysis 
At 6 weeks, the implants were more radiodense than the host trabecular bone 
allowing the general region of the remaining implant to be evident (Figure 3.5).  
However, regions of host bone immediately surrounding the implant appeared just as 
radiodense as the implant making the border between the implant and host bone 
indistinguishable in some areas. Resorption of AMBP was observed by the changes in 
radiodensity within the implant cavity.  The radiographs suggest that the composites from 
the 6C3G1L600-SDBP treatment group resorbed faster than the other groups, as 
evidenced by the presence of radiolucent zones at the implant margins.   
 
Figure III.5: Radiographs of extracted rabbit distal femurs. 
(A: 6C3G1L300-MBP, B: 6C3G1L300-SDBP, C: 6C3G1L600-MBP, D: 6C3G1L600-
SDBP. These radiographs suggests that the 6C3G1L600 group resorbed faster than the 
other groups. ) 
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Histological evaluation 
All of the histological micrographs suggest that the PUR/AMBP composite plugs 
were biocompatible, as evidenced by the absence of a significant inflammatory response.  
Furthermore, the composites did not disrupt the normal wound healing process, as 
evidenced by the presence of osteoid lining the host bone surrounding the implant.  One 
rabbit that was treated from the 6C3G1L300-SDBP group died at 2 weeks due to causes 
unrelated to the surgery. As shown in Figure 3.6, histological sections processed at this 2 
week time point suggest that the AMBP/PUR plugs remodeled by the mechanism of 
creeping substitution.
33,62
  The boundary between the implant and the host bone is well-
defined in the low magnification micrograph (Figure 3.6A).  Growth of new bone in 
apposition to the surface of the implant followed by the onset of a wall of bone forming 
around the implant can also be seen (Figure 3.6A). The onset of cellular infiltration and 
resorption of AMBP, stained tan/pink, is illustrated in Figures 3.6B-C.  Resorption is 
followed by new bone formation (Figure 3.6C).  At this early time point, there is minimal 
degradation of the polymer (blue-green color). Osteoid, stained green, lines the edge of 
the newly formed bone around the implant in Figure 3.6D.   
Low magnification micrographs at the 6 week time point (Figure 3.7) show 
differences between treatment groups.  In all of the treatment groups, a majority of the 
resorption, cellular infiltration, and remodeling occurred in the peripheral regions of the 
implant with little activity occurring in the central core of the implant.  The 6C3G1L300-
AMBP treatment group showed the least cellular infiltration, while the 6C3G1L600-
SDBP showed the greatest cellular activity (Figures 3.7A and 3.7D).  There was a 
significant amount of polymer remaining in all of the treatment groups, especially at the 
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core of the implants.  However, composites prepared with the 6C3G1L600 polyol 
appeared to degrade faster than the materials incorporating the 6C3G1L300 polyester 
triol (Figure 3.7D).  The 6C3G1L600-SDBP material supported the most extensive 
cellular infiltration and polymer degradation. As shown in Figure 3.7D, at six weeks cells 
had infiltrated throughout the entire volume of one end of the implant. Higher 
magnification micrographs (Figure 3.8) show both the resorption of allograft bone 
particles and new bone formation on their surfaces within the implant cavity.  Newly 
mineralized bone matrix formed on the surface of the allograft particles is evidenced by 
the more pronounced pink color and the dark blue osteocytes within the matrix.  Figure 
3.8A shows bridging of two allograft particles by new bone.  On some allograft particles, 
both new formation and resorption by osteoclasts appeared to occur simultaneously 
(Figure 3.8C).  New bone formation was not limited to the surface of the allograft bone 
particles, as Figure 3.8D shows ingrowth of new bone at the border of the implant.  From 
the images in Figure 3.7, remnants of polymer that has not yet resorbed can also be seen.  
In particular, an island of polymer surrounded by new bone  is evident in Figure 3.8D. 
While the continuing presence of the polymer is anticipated to delay new bone formation, 
especially for the case of bone particles completely embedded in polymer, modest 
amounts of new bone formed around the polymer remnants.  Figure 3.8D also shows that 
the host bone is lined with osteoid, suggesting future ingrowth into the implant cavity.   
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Figure III.6: Histology at 2 weeks for 6C3G1L300-SDBP treatment group. 
((A) – (D) Histological sections of the 6C3G1L300-SDBP treatment group are stained 
with Sanderson‟s rapid bone stain.  (A) At two weeks, there is evidence of bone 
apposition and the composite is encapsulated in a bony shell (1.25X). (B) – (D) Higher 
magnification images (20X) show bone apposition (orange asterisk), resorption (black 
asterisk)   and remodeling of the allograft component via the process of creeping 
substitution (20X).) 
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Figure III.7: Low magnification (1.25X) histological sections of all treatment groups at 
6 weeks. 
(A: 6C3G1L300-MBP, B: 6C3G1L300-SDBP, C: 6C3G1L600-MBP, D: 6C3G1L600-
SDBP) 
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Figure III.8: Remodeling of allograft bone particles in 6C3G1L600-SDBP treatment 
group. 
((A) – (B): New bone formation around the edge of SDBP.  Osteocytes are stained blue 
within the new bone matrix. (20X), (C): Both new bone formation and resorption of 
SDBP (10X), (D): Islands of polymer surrounded by new bone formation (20X).) 
 
Histomorphometry  
Histomorphometric analysis of the 6C3G1L300-AMBP and 6C3G1L600-AMBP 
implants (Figure 3.9) was performed to quantify the effects of polyester triol molecular 
weight on allograft resorption, cellular infiltration, polymer degradation, and new bone 
formation.  After 6 weeks implantation time, the AMBP300 implants exhibited 28.3 ± 
3.5% residual polymer compared to 29 ± 0.9% for the AMBP600 implants, which is not a 
significant difference. Furthermore, the concentration of polymer at 6 weeks was close to 
the initial concentration (32.4 vol% from the mass balance), which suggests that the 
polymer underwent only a modest amount of degradation after 6 weeks. Despite the small 
differences in polymer resorption at 6 weeks, cellular infiltration and allograft resorption 
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were accelerated in the AMBP600 composites, although differences between the two 
treatment groups were only significant (p ≤ 0.06) for allograft resorption.  However, 
although bone resorption and cellular infiltration were higher for the AMBP600 
composites, the amount of new bone formation was small for both treatment groups 
(<5%) and the difference between the treatment groups was not significant. 
 
Figure III.9: Histomorphometry of AMBP/PUR composites implanted in vivo. 
Polymer degradation, cellular infiltration, and new bone formation are accelerated in 
MBP composites incorporating a polyurethane binder with a lower crosslink density.  
Histomorphometric analysis of an active region of remodeling shows that composites 
fabricated from the 600 g/mol polyol exhibit faster polymer degradation, cellular 
infiltration, and new bone formation relative to those prepared from the 300 g/mol polyol. 
 
Discussion 
 
A variety of polymers have been utilized to augment fracture fixation devices and 
bone replacement materials. While interconnected pores are generally considered 
necessary to promote bone ingrowth into a polymeric scaffold
3,4
, pre-existing pores 
significantly reduce the initial load-bearing properties
4
 of the device.  In the present 
study, we have fabricated allograft bone/polyurethane composites that have tunable initial 
mechanical properties comparable to those of host bone.  When implanted in plug defects 
in the femoral condyles of NZW rabbits, the allograft bone component of the composites 
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was resorbed by osteoclasts, thereby creating pores in the composite into which cells 
infiltrated.  Modest polymer degradation and new bone formation were observed.  For 
some of the implants, infiltration of cells deep into the interior was observed after 6 
weeks in vivo, which is surprising for solid composites with minimal void space (e.g., 
<5% porosity).   
Several studies have described the preparation of weight-bearing composites 
incorporating various fillers (such as bioactive glass or hydroxyapatite) for orthopaedic 
applications. Composites fabricated from synthetic polymers and bioactive glass, which 
was developed in the early 1970‟s, have been reported.63  Young‟s modulus values as 
high as 13.6 GPa have been achieved for materials comprising bioglass, urethane 
dimethacrylate, 2-hydroxylethyl methacrylate, and a photosynthesizing agent.
64
  While 
this value of Young‟s modulus is close to that of cortical bone, the acrylate polymer 
component of the bioglass composites was non-degradable.  Furthermore, bioactive glass 
has a slow resorption time, typically greater than 1 year.
1,65
  Thus the combination of a 
non-degradable polymer and slowly resorbing filler is anticipated to limit the extent of 
bone ingrowth and remodeling of the composite.  Resorbable composite IM rods have 
been fabricated from hydroxyapatite (HA, 20-30 wt%) and poly(L-lactide) (PLLA) that 
exhibit bending strength and modulus up to 280 MPa and 7.8 GPa, respectively.
26
  
Resorption and new bone formation were observed after 5-7 years when HA/PLLA 
composites were implanted in NZW rabbit femoral plug defects.  In a rabbit femoral 
intramedullary (IM) rod study, bone bridging between HA and host bone was dependent 
upon the degradation rate of PLLA to allow exposure of HA particles on the surface of 
the implant.
66
  Slowly degrading PLLA implants can take up to 2 years to degrade, 
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leaving behind crystallites that have been reported to induce an inflammatory response.
67
  
In the metaphyseal region of the rabbit femur, the complete degradation of the PLLA 
occurred after 4.5 years, while the HA particles were replaced with new bone after 5.5 
years.
66
  In contrast, the AMBP/PUR composites supported rapid bone resorption and 
cellular infiltration after only 6 weeks in vivo.  Since the cells infiltrated the implants 
through resorption of the nearly continuous AMBP phase (as discussed in greater detail 
below), degradation of the PUR binder was not necessary. The histomorphometry data 
(Figure 3.8) further support the observation that polymer degradation did not precede 
remodeling, considering that the allograft bone volume fraction decreased from 67.6 
vol% to 30 – 55 vol%, a substantial reduction compared to that observed for the polymer. 
Allograft bone has been a standard of care for the treatment of orthopedic defects 
because of its osteoconductive properties.
68,69
 However, allograft devices remodel slowly 
due to the low specific surface area. By combining particulated allograft bone at volume 
fractions approaching the random close packing limit (64%
70
) with a polymer binder, we 
reasoned that it would be possible to fabricate composites that undergo more rapid 
remodeling due to the presence of a nearly continuous allograft bone surface throughout 
the implant. The extent of bone remodeling in particulated allograft bone/polymer 
composites has been reported to increase with increasing allograft bone content, with a 
dramatic increase in both cellular penetration into the implant and new bone formation at 
75wt% (~61 vol%) bone particles.
36
  In the present study, the particulated allograft 
content was increased to 79 wt% (67.6 – 67.9 vol% from the mass balance), which 
slightly exceeded the RCP limit for spheres and approached the limit for acceptable 
mechanical properties (83 wt%). At the RCP limit, bone particles were in close contact or 
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separated by a thin film, thus presenting a nearly continuous osteoconductive pathway for 
cells to penetrate the implant by resorbing allograft and migrating into the resulting 
newly formed pores (Figure 3.10A, B, and C).  However, in some cases, non-ideal 
mixing of the reactive composite paste resulting in polymer-rich regions where the 
continuous bone phase was partially interrupted (Figure 3.10C).  While cellular 
infiltration slowed in the polymer-rich region, cells further infiltrated the implant in an 
adjacent region where there was closer contact between bone particles (Figure 3.10B).  
Non-ideal mixing is not surprising due to the high viscosity of the reactive two-
component PUR binder, especially in the case of the 600 MW groups.  
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Figure III.10: The process of creeping substitution is accelerated by the presence of a 
continuous, percolated bone phase. 
(Remodeling of MBP/PUR composite occurring around the un-remodeled core.  (A) 10X 
micrograph near the boundary between an actively remodeling region and the un-
remodeled core. (B) An area of active of active remodeling just outside the un-remodeled 
core (20X). (C) A region enriched in polymer where the residual polymer hinders the 
penetration of cells (20X). (D) A region where bone particle contacts provide a pathway 
for infiltration.) 
 
A majority of the composite treatment groups showed increased remodeling 
activity at the ends of the implant (top and bottom), particularly when the implant was 
both in direct apposition to the host trabecular bone and exhibited regions enriched in 
allograft due to non-ideal mixing.  Figure 3.11 shows the top of a composite from the 
AMBP300 group that underwent both extensive cellular infiltration as well as polymer 
degradation, and exhibited greater new bone formation.  Cellular infiltration, allograft 
resorption, polymer degradation, and new bone formation were substantially higher in 
this particular implant compared to other samples in the AMBP300 treatment group, 
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presumably due to close contact between an allograft-rich region of the implant and host 
bone at the base of the implant. With the exception of the implant shown in Figure 3.11, 
composites prepared from the 600 MW groups exhibited faster polymer degradation, 
cellular infiltration, and allograft resorption due to the lower cross-link density of the 
PUR networks synthesized from 600 g/mol polyester triols.  The dramatically faster rate 
of remodeling of bone/polymer composites (~6 wks) relative to the HA/PLLA implants 
(~4 yrs) is conjectured to result from either the greater bioactivity of AMBP, the presence 
of a particulated continuous osteoconductive phase, or both. In the AMBP/PUR 
composites, resorption of the bone particles is thus independent of polymer degradation 
because the particles are already exposed on the surface of the implant, unlike the 
HA/PLLA composites. 
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Figure III.11: Low magnification histology (2.5x). 
(There is extensive cellular infiltration, polymer degradation, and new bone formation in 
a 6C3G1L300-MBP implant. (B) – (C) Higher magnification (20X). (D) – (E) high 
magnification (40X).) 
 
The AMBP/PUR implants initially remodeled by creeping substitution, 
characterized by resorption of allograft followed by new bone formation.
62,71
  However, 
the rate at which osteoclasts resorbed allograft and cells infiltrated the implant strongly 
depended on the formulation of the composite (Figure 3.7D).  Cellular infiltration was 
highest for the 6C3G1L600-AMBP group, where cells had penetrated deep into the 
interior of the non-porous implant after only 6 weeks. As a result of these processes, an 
outer ring of demineralized tissue with a modest amount of new bone formation was 
created around the un-remodeled core.  It is conjectured that as the resorption and 
remodeling proceeds, cells will penetrate further into the core of the implant and new 
bone will form behind the resorption front, resulting in re-mineralization of the entire 
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implant.  Thus the allograft particles function as a biologically active “porogen”, wherein 
pores are created as the allograft particles are resorbed, followed by cellular migration, 
matrix deposition, and new bone formation in the newly formed pores.  At the short 6 
week time point investigated in this study, the amount of new bone formation was 
modest.  Considering that weight-bearing implants must maintain a threshold mechanical 
strength during the remodeling process, it is desirable that that the resorption front be as 
sharp as possible, since a broad resorption front would reduce the mechanical properties 
of the implant to levels substantially below its initial value.  Considering the well-known 
effects of angio-osteogenic factors, such as rhFGF-2 and rhBMP-2, on enhanced 
mineralization of porous polymeric scaffolds, it is conjectured that addition of a suitable 
growth factor would accelerate new bone formation, thereby possibly preserving the 
weight-bearing mechanical properties of the implant throughout the remodeling process.   
Interfacial bonding is well-known to enhance the mechanical properties of 
composites.  The absorbance data in Figure 3.2 show that AMBP in contact with FITC 
exhibited a higher absorbance than the negative (AMBP + buffer with no FITC) and 
positive (FITC solution in a tissue culture plastic well plate with no AMBP) controls. The 
higher fluorescent absorbance observed for FITC-treated AMBP is conjectured to result 
from covalent binding of the isothiocyanate (N=C=S) groups in FITC with nucleophiles 
such as amine and hydroxyl groups present in the proteins in the allograft bone. SDBP 
treated with FITC exhibited significantly higher absorbance relative to FITC-treated 
AMBP, which is consistent with the XPS data showing that surface demineralization 
increased the concentration of protein on the surface. These data suggest that the amine 
and hydroxyl groups on the surface of the allograft particles react with the isocyanate 
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(N=C=O) groups in the LTI to form urea and urethane bonds, respectively, and that 
surface demineralization would increase the mechanical properties of the composites.  
Surprisingly, the data in Table 3.2 show that composites fabricated from SDBP exhibited 
comparable mechanical properties to those prepared from AMBP.  Thus while surface-
demineralization enhanced the reactivity of the allograft surface, it did not significantly 
increase the mechanical properties.  Non ideal mixing is a contributor to the negligible 
effect of SDBP on mechanical properties as polyol can coat the surface of SDBP, 
preventing the reaction between the bone surface and isocyanate.   
The Takayanagi models have been applied to model the mechanical properties of 
two-phase polymer blends and composites.  Assuming the geometry of a circular cross 
section of the filler is isometric, the Takayanagi models yield the following equations for 
the compressive modulus E of the composite as a function of the volume fraction and 
compressive modulus for each phase
49
:   
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where 1 is the volume fraction allograft bone, E1 is the compressive modulus of the 
allograft bone particles, 2 is the volume fraction PUR, and E2 is the compressive 
modulus of the PUR component.  Eqs (1) – (4) were derived assuming different 
composite morphologies.  Eq (1), which is equivalent to the well-known Reuss model
72
, 
assumes that neither phase is continuous in space, and eq (4), which is equivalent to the 
well-known Voigt model
73
, assumes that both the allograft particles and PUR binder are 
continuous in space.  More physically relevant morphologies intermediate to these upper 
(Voigt model) and lower (Reuss model) bounds are described by eq (2), which assumes 
that the PUR binder is continuous, and eq (3), which assumes that the allograft particles 
are continuous. Values of the composite compressive modulus calculated from each of 
these conditions are listed in Table 3.3.  
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Table III.3: Takayanagi model calculations for compressive modulus of bone/polymer 
composites.  
(All composites incorporated 79 wt% allograft bone particles. EC denotes calculated 
compressive modulus calculated from the Takayanagi models.) 
 
Property 
MBP300 SDBP300 MBP600 SDBP600 
Bone density, g cm
-3
 2.3 2.3 2.3 2.3 
PUR density, g cm
-3
 1.274 ± 
0.005
74
 
1.274 ± 
0.005
74
 
1.290 ± 
0.003 
1.290 ± 
0.003 
Bone modulus, GPa
75
 18.6 18.6 18.6 18.6 
PUR modulus, GPa 1.427 ± 
0.039
74
 
1.427 ± 
0.039
74
 
0.988 ± 
0.055 
0.988 ± 
0.055 
Volume fraction bone, % 67.60% 67.60% 67.90% 67.90% 
Volume fraction polymer, 
% 
32.40% 32.40% 32.10% 32.10% 
EC, both phases discont., 
GPa 
3.79 3.79 2.76 2.76 
EC, PUR continuous, GPa 5.12 5.12 3.87 3.87 
EC, MBP continuous, 
GPa 
9.36 9.36 9 9 
EC, PUR and MBP 
continuous, GPa 
13 13 12.9 12.9 
EC, experimental, GPa 6.01  0.34 5.52  0.11 3.05  0.64 3.66 0.39 
 
A value of 18.6 GPa was used for the modulus of allograft cortical bone.
74
  The volume 
fraction of allograft calculated from the mass balance was ~68 vol%, which exceeds the 
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spherical random close packing (RCP) limit of 64 vol%. Histomorphometric analysis of 
the regions near the center of the implant (which were not penetrated by cells) yielded 
allograft volume fractions ranging from 66 – 74 vol% (Figure 3.4). Qualitative 
examination of the histological sections showed that the AMBP filler was nearly 
continuous throughout most of the implant, but there were some regions enriched in 
polymer and depleted in bone particle-particle contacts.  Thus, the mass balance and 
histomorphometric data suggest that the AMBP filler was continuous and percolated 
throughout most of the implants, indicating that the compressive modulus of the 
composites is most accurately predicted by eq (3).  Interestingly, the experimental values 
of the compressive modulus were within 1 GPa of the calculated values assuming a 
continuous PUR phase, but 3 – 6 GPa less than those calculated assuming a continuous 
AMBP phase.  Considering that surface demineralization enhances allograft reactivity but 
not composite mechanical properties, insufficient interfacial bonding cannot explain the 
lower experimental values of the compressive modulus relative to the Takayanagi model 
predictions. Closer examination of the histological sections near the core (Figure 3.4) 
revealed that not all of the particle-particle interactions were point contacts, but rather 
extensive areas of contact where there was minimal polymeric binder present between the 
allograft particles, thereby creating defects along which cracks could propagate.  
However, it is conjectured that these defects also accelerated allograft resorption by 
increasing the area available for cellular infiltration. Thus biomechanics and remodeling 
are inter-related, such that the mechanical properties are reduced as the RCP limit is 
approached, but the processes of resorption and cellular infiltration are accelerated. 
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Conclusions 
 
Non-porous AMBP/PUR composites are a high strength, osteoconductive 
biomaterial suitable with initial mechanical properties suitable for weight-bearing 
applications.  The mechanical properties and cellular infiltration rate can be tuned for 
specific applications by manipulating the molecular weight of the polyester polyol used 
during synthesis.  Cellular infiltration and new bone formation were observed in the 
interior of the implant at 6 weeks, which is surprising for composites with such low 
porosity (<5%).  Osteoclast-mediated resorption of the allograft particles created pores 
into which cells migrated, followed by deposition of new collagen matrix and bone 
formation.  Due to the time lag between resorption and re-mineralization, a resorption 
front was observed at 6 weeks, which is anticipated to reduce the mechanical properties 
as the implant remodels.  Although further time points are needed to investigate the full 
resorption and the profile of new bone formation, the findings from this study suggest 
that AMBP/PUR composites may have potential application as biologically active 
weight-bearing devices for bone tissue engineering.  
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CHAPTER IV.  
Synthesis, characterization, and remodeling of porous allograft mineralized bone 
particle/polyurethane bone void filler in a rat model 
 
 
Introduction 
 
 There is a well-recognized need for improved biomaterials for the treatment of bone 
defects. Although autologous bone grafts are considered to be the standard of care due to 
their osteoconductive and osteoinductive properties, there is a limited supply of autograft 
and the harvesting procedure introduces potential donor site morbidity.  Due to these 
limitations, considerable effort has been expended toward the development of synthetic 
bone graft materials. Alternative biomaterials must be biocompatible, resorbable, support 
cellular attachment and proliferation, and support the ingrowth of new bone tissue.  
 Injectable biomaterials offer several advantages relative to implantable biomaterials 
due to their ability to cure in situ, thus conforming to irregularly-shaped defects.  Some 
commercially available injectable materials marketed as bone void fillers include calcium 
phosphate-based bone cements.
1-4
 These biomaterials are osteoconductive, have 
compressive strengths comparable to trabecular bone (e.g., 5 – 40 MPa), and have fast 
setting times (~10 – 15 minutes).2,4  Although calcium phosphate bone cements are 
porous, the pore size is in the range of 1 m.5  This renders the material relatively 
impermeable to cellular infiltration leading to a slower rate of resorption and new bone 
formation.
2,6
  Additionally, calcium phosphate cements are subject to brittle fracture and 
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graft migration, potentially leading to infections and requiring additional surgeries for 
repair or removal.
4,7,8
  For craniofacial applications, mechanical failure of bone cements 
has been attributed to pulsatile forces from the blood supply of the dura.
6,8,9
  
 With the advent of technologies for sterilization and viral inactivation, 
mineralized human bone allografts have emerged as a preferred implant type for weight-
bearing orthopaedic and spinal applications.
10
 While concerns have been raised regarding 
the risk of disease transmission, it is significant that Osteotech has produced >3.5M grafts 
from >40,000 donors since 1991 with no confirmed report of disease transmission.
11
  
Allografts have excellent weight-bearing biomechanical properties and they undergo 
extensive osseous integration by osteoclasts and osteoblasts.  Furthermore, these 
materials contain all the physiologically relevant elements and salts, such as silicon, 
boron, and strontium, in the exact proportions at which they are most effective.
12
  
However, the anatomy of the donor bone limits the reproducibility and range of 
mineralized allograft shapes available for clinical use.
10
 Furthermore, while the extent of 
integration is generally considered adequate, remodeling of the graft seldom exceeds 
50%, which limits its use in the clinic.
13
 Since remodeling proceeds from the external 
surface to the interior through the process of creeping substitution
14
, the limited 
remodeling of allograft devices is conjectured to be due in part to their low specific 
surface area, which scales inversely with particle diameter. By processing the allograft 
cortical bone into small particles < 1 mm, the specific surface area is increased, which 
can lead to incomplete remodeling.
15
 
 Two-component polyurethanes (PUR) are a potentially useful class of biomaterials 
due to their potential injectability. By mixing a polyisocyanate with a hardener 
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comprising a polyol, water, and tertiary amine catalyst, a reactive liquid mixture is 
formed that subsequently cures to form a solid porous elastomeric scaffold within 10 – 15 
minutes in situ.
16
 Use of isocyanate-functional prepolymers mitigates the toxicity hazards 
associated with injection of monomeric polyisocyanates.  Biodegradable PUR scaffolds 
synthesized from lysine-derived and aliphatic polyisocyanates have been shown to 
degrade to non-toxic compounds
17
 and support cell attachment and proliferation in vitro.  
These materials also have tunable degradation rates, which are shown to be highly 
dependent on the choice of polyol and isocyanate components.
18
 Polyurethanes have 
tunable mechanical properties, which can also be enhanced with the addition of fillers,
19
 
and exhibit elastomeric rather than brittle mechanical properties. While many synthetic 
polymers (such as poly(-ester)s and polyurethanes) support modest bone ingrowth, the 
addition of osteoconductive fillers such as -TCP has been reported to increase not only 
the mechanical properties, but also the extent of bone ingrowth and new bone 
formation.
20
 
 In previous studies, the osteoconductive filler content ranged from 10 – 40 wt% (~4 
– 18 vol%).  Due to its relatively low volume fraction, the filler was completely 
embedded in polymer; thus the rate of remodeling scaled with the rate of polymer 
degradation.
21
 Furthermore, the particle size of the mineralized filler was generally < 20 
m, which is below the preferred size range for remodeling by creeping substitution.21  In 
the present study, we aimed to accelerate the rate of remodeling of bone/polymer 
composites by incorporating >100 m allograft bone particles and a modest (e.g., 30 - 
60%) amount of porosity.  We reasoned that increasing the allograft content while 
maintaining porosity would accelerate cellular infiltration into the composites through 
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both migration of cells into open pores, as well as remodeling of allograft particles by 
creeping substitution.  Thus we investigated the effects of porosity on the mechanical and 
processing properties of bone/polyurethane composites comprising 45 – 50wt% (31 – 36 
vol%) allograft bone particles, which was the highest allograft loading achieved for an 
injectable system. To evaluate the in vivo biocompatibility and remodeling of the 
bone/polymer composites, the composition representing an optimum balance of porosity 
and initial mechanical properties was injected into bilateral femoral condyle plug defects 
in athymic rats. 
 Methods and Materials 
 
Materials 
 -Caprolactone, the blowing catalyst bis (2-dimethylaminoethyl) ether (DMAEE), 
the gelling catalyst triethylene diamine (TEDA), dipropylene glycol (DPG), and 
poly(ethylene glycol) (PEG, MW 200-Da) were all obtained from Sigma-Aldrich (St. 
Louis, MO). Glycolide and D,L-lactide were purchased from Polysciences, Inc. 
(Warrington, PA).  The tertiary amine gelling catalyst TEGOAMIN33 was received from 
Goldschimidt (Hopewell, VA). Lysine Triisocyanate (LTI) was obtained from Kyowa 
Hakko USA. Bovine (B-MBP) and human (H-MBP) mineralized bone particles (MBP) 
were obtained from Osteotech, Inc. (Eatontown, NJ).  With the exception of -
caprolactone, PEG, DMAEE, and glycerol, all materials were used as received. Prior to 
use, PEG and glycerol were dried at 10 mm Hg for at least 4 hours at 80°C, and -
caprolactone was dried over anhydrous magnesium sulfate. DMAEE was blended with 
DPG at a 70:30 mass ratio. 
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Polyester macrotriol synthesis and characterization 
 Polyester triols of 900-Da molecular weight, T6C3G1L900, were prepared with a 
trifunctional glycerol starter and 60 wt% e-caprolactone, 30% glycolide, 10% D,L-
lactide, and stannous octoate catalyst (0.1%), as previously described.
22
  These 
components were mixed with mechanical stirring in a three-neck flask for 36 hours under 
argon at 140°C. The product was then dried under vacuum for at least 24 hours at 80°C, 
followed by the preparation ofa concentrated solution in dichloromethane and washing 3x 
with hexane.
22
 The hydroxyl (OH) number was measured by titration according to ASTM 
D4274-99 Method C
22
, and the molecular weight was measured by GPC (Waters Breeze) 
using two MesoPore 300x7.5mm columns (Polymer Laboratories, Amherst, MA) in 
series and a stabilized tetrahydrofuran (THF) mobile phase. The polyol hardener was 
produced by mixing the appropriate amounts of T6C3G1L900, deionized (DI) water, 
DMAEE, and TEGOAMIN33 in a Hauschild SpeedMixer™ DAC 150 FVZ-K vortex 
mixer (FlackTek, Inc., Landrum, SC).  In an alternative method, a high NCO quasi-
prepolymer was synthesized by adding the polyester to hexamethylene diisocyanate 
(HDI). The %NCO of the prepolymer was measured by titration using ASTM D2572-
97
23
, and the hydroxyl number calculated from the mass balance and measured %NCO.  
Prepolymer synthesis and characterization  
The LTI-PEG prepolymer was synthesized by adding poly(ethylene glycol) (200 
g/mol, PEG200) dropwise over the course of 1 hour to LTI in a three-neck flask while 
stirring under argon. The mixture was then stirred for 24 hours at 45°C, and the 
subsequently dried under vacuum for at least 24 hours at 80°C. The NCO:OH equivalent 
ratio of the prepolymer was 3.0:1.0.  The %NCO was measured by titration according to 
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ASTM D2572-97
24
, the molecular weight distribution was measured by GPC as 
described previously, and the viscosity was determined using a Brookfield viscometer.  
The prepolymer was stored under argon at 4
o
C. 
Preparation and characterization of surface-demineralized and defatted allograft bone 
particles  
Mineralized bovine bone particles (B-MBP) were sonicated in 0.1M HCl for 90 
seconds. An equal volume of DI water was subsequently added, and the particles 
subsequently filtered and rinsed with DI water. This entire process was repeated for a 
total of two times, and the particles were subsequently rinsed with 70% ethanol and dried. 
The resulting surface-demineralized bone particles (SDMBP) were then lyophilized for a 
minimum of 14 hours at 0.10 mbar.  To prepare defatted mineralized bovine bone 
particles (DFMBP), mineralized bone particles were stirred with a 50/50% volume 
solution of acetone/chloroform in a volumetric ratio of 1:10 for at least 48 h. Mineralized 
human bone particles (H-MBP) were used as received from Osteotech.  H-MBP was 
prepared by comminuting debrided and cleaned cortical bone in a mill. Ground particles 
were sieved between 106-500 µm diameter and defatted in 70% denatured alcohol for at 
least an hour. Particles were washed with sterile deionized water, lyophilized for a 
minimum of 6 hrs at -35 ºC, and by vacuum-dried for a minimum of 12 hrs at 35 ºC and 
500 mtorr. Lyophilized bone particles were treated with supercritical carbon-dioxide at 
105
0
C for at least 25 minutes.  The bone was packaged under dry argon and gamma 
irradiated at 25-35 KGy. 
B-MBP, SDMBP, DFMBP, and H-MBP were imaged by scanning electron 
microscopy (Hitachi S-4200 SEM, Finchampstead, UK). The skeletal density, which 
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accounts for both the volume of the solid as well as the blind (e.g., inaccessible) pores, 
was measured by gas pycnometry using nitrogen as the penetrating gas (Micromeritics, 
Norcross, GA). The skeletal density (MBP, see Eq (1) below) was used to calculate the 
porosity of the composites because it was assumed that the PUR binder would wet the 
external pores but not the internal (blind) pores. The particle size distribution was 
measured using a Saturn DigiSizer 5200 V1.12 (Micromeritics, Norcross, GA).  
 The surfaces of B-MBP, SDMBP, DFMBP, and H-MBP were characterized by 
XPS using a PHI 5000 VersaProbe XPS with a 25W monochromatic Al K- X-ray 
source and a 100-µm spot size. Survey and high resolution spectra were collected using 
187.85 and 23.5 eV pass energies respectively. All the measurements were done using a 
45º take-off angle and charge neutralization under ultrahigh vacuum. Analysis of the data 
was performed using the software CasaXPS Version 2.3.14 (© 1999-2008 Neal Fairley). 
Synthesis and characterization of the injectable MBP/PUR composite void filler  
 The complete process for preparation of injectable MBP/PUR composites is 
summarized in Figure 4.1. To prepare the void filler, the hardener, LTI-PEG prepolymer, 
and allograft bone were charged to a mixing cup and hand-mixed for 1 minute.  
Composites incorporating bovine bone were prepared with 50 wt% (36 vol%) allograft 
particles, the maximum that could be successfully injected using the 5-ml syringe (for H-
MBP it was 45 wt% (30 vol%)).  The relative amounts of the prepolymer and hardener 
components were calculated assuming an index of 115 (the index is defined as 100 x (no. 
of NCO equivalents/no. of OH equivalents)).
25
  The OH titration, NCO titration, and 
GPC measurement yielded different values of the OH number that bracketed the 
theoretical OH number; therefore, the theoretical OH number was used to formulate the 
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composites.  This approach has been reported to yield PUR networks with minimal sol 
fraction when indexed at 115.
19
 The resulting reactive paste was subsequently transferred 
into a 5-ml syringe and injected into a mold.  The composites were cured overnight at 
ambient temperature prior to the density measurements. The density of the scaffolds was 
determined from mass and volume measurements of triplicate cylindrical samples with 
12 mm diameters and lengths varying from 15–25 mm. The porosity, defined as the 
volume fraction pores, was calculated from the composite foam density
16
, which was 
measured gravimetrically: 
   1

c
     (1) 
where   is the average measured composite foam density (cored) and c is the density of 
the composite assuming there are no pores: 
 c 
1
xB
B

1 xB
P
    (2) 
In eq (2),  is the porosity, F is scaffold density, MBP = 2100 kg-m
-3
 is the density of 
MBP (measured by pycnometry), PUR = 1200 kg-m
-3
 is the density of PUR (measured 
gravimetrically), and xB is the weight fraction of MBP. Data are presented as mean ± 
standard deviation of triplicate samples. Scanning electron microscope (SEM) 
micrographs were obtained using a Hitachi S-4200 (Finchampstead, UK), and pore size 
was measured using MetaMorph 7.1 Image Analysis software (MDS Analytical 
Technologies, Mississauga, Canada). 
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Figure IV.1: A schematic of the synthesis of injectable MBP/PUR composites. 
MBP, mineralized bone particle; PUR, polyurethane; LTI, lysine triisocyanate; PEG, 
poly(ethylene glycol); DMAEE, bis-(2-dimethylaminoethyl) ether; DPG, dipropylene 
glycol; TEDA, triethylene diamine. 
 
Working and tack-free times 
 The working time is defined in the ISO9917 standard as “the period of time, 
measured from the start of mixing, during which it is possible to manipulate a dental 
material without an adverse effect on its properties.”25  For a two-component 
polyurethane, the working time is determined by the gel point, the time at which the 
crosslink density of the polymer network is sufficiently high that the material gels and no 
longer flows.
25
  The working time was measured by loading the syringe with the reactive 
composite and injecting <0.25ml every 30s. The working time was noted as the time at 
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which the material was more difficult to inject, indicating a significant change in 
viscosity. For polymeric materials, the tack-free time (TFT) is an effective measure of the 
time required for the material to cure to form a solid elastomer. Thus the TFT 
approximates the setting time reported for bone cements, and is defined as the time at 
which the material could be touched with a spatula with no adhesion of the spatula to the 
foam.  At the TFT, the wound could be closed without altering the properties of the 
material. 
Mechanical Testing 
Cylindrical samples with 12mm diameters and lengths ranging from 10–30mm 
were prepared. Samples designated “wet” were submerged in phosphate-buffered saline 
(PBS) for 24 hours prior to testing.  Samples were tested in compression mode using the 
MTS Bionix system  (Eden Prairie, MN  USA) with 1 kN load cell.  The displacement 
rate was adjusted on a lot-by-lot basis maintain a relatively constant strain rate for all test 
samples.  The displacement rate varied between 2 mm/min and 6 mm/min; this 
corresponds to a strain rate of approximately 20-25%/min for each test sample. Data are 
presented as mean ± standard deviation of triplicate samples. 
Viscosity Measurements 
A TA Instruments AR-G2 rheometer with a Peltier Plate Temperature Control Unit 
was used to determine the initial viscosity of the MBP/PUR composite without the 
catalyst mix to prevent the material from curing and adhering to the Peltier plate. The 
composite was prepared by mixing the prepolymer, polyol, and allograft components and 
mixing for 60s.  The test fixture was a set of 40mm parallel plates and the test was carried 
93 
 
at 20C. The viscosity was measured dynamically with a frequency sweep from 0.1 rad/s 
to 100 rad/s and controlled strain amplitude of 0.02%. 
In Vitro Degradation 
 Samples (6mm diameter × 1mm long) were individually placed in small vials, 
immersed in PBS, and stored at 37°C under mechanical agitation. At each time point 
samples were immersed in DI water for at least 1 hour for a total of 2 water changes at 
room temperature. The samples were then lyophilized for 16 hours, and weighed to 
determine mass lost. Data are presented as mean ± standard deviation of quadruplicate 
samples. 
In vivo study 
 An athymic rat study was conducted at the Osteotech rodent facility, which is 
fully compliant with the American Association for Laboratory Animal Sciences 
guidelines. Two technicians certified by the American Association for Laboratory  Animal 
Sciences (AALAS) performed the surgery.   The polyol hardener, LTI-PEG prepolymer, 
and human MBP (H-MBP) were sterilized by gamma irradiation at a dosage of 25 – 35 
kGy.  The components were hand-mixed by charging the polyol, allograft bone particles, 
and prepolymer to a 20-ml cup and mixing for 1 minute. The catalyst solution comprising 
5% TEDA and 1.2 pphp water in DPG was subsequently added and the reactive paste 
mixed for another 30 s.  The mixture was transferred to a syringe and injected into 4-mm 
unicortical femoral plug defects in athymic rats.  Two approaches were pursued to 
investigate the effects of wound closure time on material properties.  In one treatment 
group, the material was injected into the defect and the wound immediately closed. In the 
second treatment group, the material was injected into the defect and allowed to expand 
94 
 
for 15 minutes before the wound was closed. Bleeding occurred primarily when the 
defects in the bone were drilled. The defects were immediately packed with gauze to dry 
the wound site, and the sample subsequently injected. For the samples where wound 
closure was delayed for 15 minutes, no additional bleeding was observed between the 
time of injection and the time of wound closure. After 3 weeks, the femurs were 
extracted, fixed in neutral buffered formalin, and imaged by CT.  The bones were then 
decalcified with 10% formic acid solution followed by dehydration in increasing 
concentration of alcohol followed by a clearing agent. Finally, samples were soaked in in 
glycidyl methacrylate (GMA) and embedded in GMA.  Post curing, 4-6 m thin sections 
were cut, mounted on slides, and stained with toluidene blue/basic fuchsin mixture. 
Slides were washed in water followed by dehydration in increasing concentration of 
alcohol followed by a clearing agent. Dehydrated slides were cover-slipped and prepared 
for micrographs. 
Results 
 
Maximum loading of bone in the composites 
 One objective of the present study was to synthesize MBP/PUR composite scaffolds 
at the highest bone fraction that could be injected through a 12-ga syringe needle. While 
for formulation purposes it is easier to express the bone content in terms of the weight 
fraction (or wt%), the volume fraction MBP controls the viscosity of the suspension and 
is calculated from the weight fraction xMBP as follows:  
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MBP 
xMBP
MBP
xMBP
MBP

xPUR
PUR
   (3) 
The highest weight fraction of bone particles that could be ejected from a standard 
laboratory 3-ml syringe was found to be 50 wt% (36.0 vol%) for B-MBP and 45 wt% 
(31.1 vol%) for H-MBP. Therefore, all subsequent experiments were performed at these 
conditions.  
Characterization of reactive PUR intermediates 
 The %NCO of the prepolymer was measured to be 22.8%, which is in good 
agreement with the theoretical value of 23%. The viscosity was measured to be 21,000 cP 
using a Brookfield viscometer.  As shown in Table 4.1, the molecular weight of the 
prepolymer is broadly distributed, ranging from monomeric LTI to the LTI-PEG-LTI-
PEG-LTI-PEG-LTI-PEG-LTI adduct comprising 5molecules of LTI and 4 molecules of 
PEG.  This observation is consistent with previously reported data for polyurethane 
prepolymers, which are typically characterized by a broad molecular weight 
distribution.
16
   
 The molecular weight and OH number of the polyester macrotriol are listed in 
Table 4.2.  The number-average molecular weight was measured to be 1405 g/mol, 
compared to the theoretical value of 900 g/mol.  However, GPC is a relative measure of 
molecular weight, and is therefore not as useful for formulating two-component 
polyurethanes, which requires the absolute molecular weight.  The OH number is a more 
reliable value for formulating the PUR composition.
16
 While the theoretical OH number 
was 187 mg KOH/g, the measured value was 153 mg KOH/g, and the calculated value 
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from the prepolymer %NCO titration was 212 mg KOH/g.  Considering that the 
theoretical value of the OH number was between the two measured values, the theoretical 
value was used to formulate the polyurethanes, as reported previously.
2,6
 
 
Table IV.1: Molecular Weight Distribution of Lysine Triisocyanate-Poly(Ethylene 
Glycol) Prepolymer. 
 
 
 
 
 
Table IV.2: Characterization of Polyester Macrotriol. 
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Characterization of the allograft bone particles   
 SEM images of B-MBP, SDMBP, DFMBP, and H-MBP are shown in Figure 4.2.  
The B-MBP particles had a mean size (measured by SEM) of 175 ± 91 m (Table 4.3), 
and the H-MBP particles had a mean size of 98 ± 48 m.  Considering that defatting and 
surface-demineralization only affected the external surfaces of the particles, these 
processes had negligible effects on the skeletal density and mean size of the particles. The 
variation in skeletal densities (measured by helium pycnometry) was minimal, ranging 
from 2.13 – 2.20 g cm-3 for all four particle treatment groups (Table 4.3).   The 
compositions of the surfaces of the bone particles, as measured by XPS, are also 
presented in Table 4.3.  B-MBP was extensively covered with a layer of fat, as evidenced 
by the high carbon content and low oxygen, calcium, and phosphorous concentration. 
Defatting the bone successfully removed the layer of fat on the surface, as shown by the 
reduction in carbon and increase in oxygen, calcium, and phosphorous concentrations.  
Similarly, surface-demineralization effectively removed the mineral content from the 
surface of the allograft particles.  The surface of B-SDMBP is depleted in calcium and 
phosphorous but enriched in carbon and nitrogen, indicating that the surface of the 
allograft has been partially demineralized.  
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Figure IV.2: Scanning electron microscopy images of allograft bone particles. 
(A: Bovine MBP, B: SDMBP, C: DFMBP, and D: human MBP. SDMBP, surface-
demineralized bone particle; DFMBP, defatted mineralized bovine bone particle.) 
 
 
Table IV.3: Characterization of Bovine and Human Allograft Bone Particles. 
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Density and porosity of the injectable composites  
 The density of the injectable composites was adjusted by varying the concentrations 
of the catalysts and water, as well as the processing technique.  In initial experiments 
with SDMBP, allograft composite foams were prepared using published techniques, 
wherein a hardener was first prepared by combining the polyester triol, catalyst, and 
water to form a hardener component.
4,7,8
 While previous studies required the use of a 
fatty acid-derived stabilizer and pore opener to generate small (e.g., <1 mm) pores, 
scaffolds synthesized from LTI-PEG prepolymer did not require these components to 
achieve the targeted porosity and pore size distribution. The SDMBP component was 
added to the hardener and mixed by hand for 30s, followed by addition of the prepolymer 
and mixing for 60s.  The material was then charged to a 3ml syringe and injected into a 
mold.  As shown in Figure 4.3a, in the presence of the tertiary amine catalyst triethylene 
diamine (TEDA, added at a concentration of 0.8 parts per hundred parts polyol (pphp) as 
a 33% solution in dipropylene glycol), the porosity of SDMBP/PUR composites varied 
over the range of 2 – 48%.  Even at higher water concentrations it was not possible to 
increase the porosity beyond 50%.  TEDA is a potent gelling catalyst that preferentially 
catalyzes the isocyanate-polyol reaction, but it also has some activity toward the 
isocyanate-water blowing reaction.
26
  In the presence of DMAEE, the maximum 
achievable porosity was increased to 70%, which is consistent with the fact that DMAEE 
is a tertiary amine catalyst that preferentially catalyzes the isocyanate-water blowing 
reaction relative to the isocyanate-polyol gelling reaction.
27
  To investigate the effects of 
surface chemistry of the bovine bone particles on the density of the materials, composite 
foams were also prepared using bovine DFMBP in the hardener process with no 
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DMAEE.  As shown in Figure 4.3, the composition of the bone surface had a dramatic 
effect on the porosity. The lower porosities achieved with SDMBP in the absence of 
DMAEE are conjectured to result from adsorption of water in the hardener to the 
hygroscopic demineralized layer on the surface of the bone. 
 An important limitation of the two-component hardener process was the storage 
stability of the hardener component. When the hardener component comprising polyol, 
water, and catalyst was stored for >3 days at 37
o
C and subsequently used to prepare 
composite foams, the resulting materials exhibited dramatic (e.g., >10 – 20%) changes in 
porosity. In order to prepare an injectable composite with acceptable storage stability, the 
two (liquid) component process was modified to an alternative three (liquid)-component 
process wherein the TEDA catalyst (0.8 pphp) and water were dissolved in a dipropylene 
glycol (DPG) solution.  Another advantage of the three-component process is that the 
volume of DPG could be increased to yield a sufficiently large solution volume that can 
be reproducibly filled in a syringe (e.g., ~200 l for a clinically relevant batch size of 5g). 
Allograft/PUR composite foams were synthesized by first mixing the polyol and 
DPG+catalyst+water solution for 60s, followed by addition of allograft particles, and 
finally addition of the LTI-PEG prepolymer. The resulting reactive paste was mixed for 
30s, charged to a 3-ml syringe, and injected into a 3-ml polypropylene mold. There were 
no significant differences in the porosity of the composite foams between the two- and 
three-component processes. 
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Figure IV.3: SDMBP/PUR scaffold porosity as a function of water concentration at 
varying concentrations of DMAEE. 
The TEGOAMIN concentration was 1.8 pphp (0.6 pphp TEDA) for all samples. Data are 
presented as mean standard deviation of triplicate samples. pphp, parts per hundred parts 
polyol. 
 
Mechanical properties 
 As anticipated, the mechanical properties of the scaffolds are highly dependent on 
the porosity. Figure 4.4 shows the compressive stress-strain curves of the SDMBP/PUR 
scaffolds with porosities ranging from 38 – 60%.  Figure 4.5 shows that the compressive 
strength of the SDMBP/PUR dry scaffolds varied from 4.38 – 9.47 MPa as the porosity 
was reduced from 50 to 30%. The compressive modulus of the scaffolds ranged from 
173.4 – 444.1 MPa in the same porosity range, as shown in Figure 4.6. For the wet 
samples, the compressive strength of the scaffolds varied from 4.06 – 12.88 MPa, while 
the compressive modulus varied from 53.2 – 331.5 MPa as the porosity decreased from 
47 to 30%. However, the wet 60% porosity scaffolds exhibited substantially lower 
mechanical properties, with compressive strength 0.167 MPa and modulus 3.11 MPa.  
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These compressive properties are in the range previously reported for unfilled PUR 
scaffolds.
28
 For composites with the same porosity, there were no significant differences 
in modulus or strength between materials prepared from SDMBP or DFMBP.  
Considering that the reinforcement of mechanical properties resulting from the allograft 
component was retained at porosities ≤50%, the targeted porosity was selected as 40% 
for in vivo experiments. 
 
Figure IV.4: Compressive stress–strain curves for the 38%, 47%, and 60% porosity 
scaffolds fabricated from SDMBP. 
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Figure IV.5: Compressive strengths of dry and wet 50 wt% (36 vol%) SDMBP/PUR 
scaffolds at porosities ranging from 30% to 60%. 
 
 
Figure IV.6: Compressive moduli of dry and wet 50 wt% (36 vol%) SDMBP/PUR foam 
scaffolds at varying porosities. 
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Porosity and pore size 
 SEM images of the allograft/polymer composites are shown in Figure 4.7 for 
composites with porosities of 35, 47, and 65%. Allograft bone particles (outlined in 
black) are dispersed throughout the scaffold, and are generally separated from one 
another by a polymer film. The pore size distribution in the interior of the composite was 
measured by image analysis of the SEM micrographs.  While the pore size distribution at 
the surface of the composite is anticipated to strongly influence cellular infiltration, 
characterization of the pore size distribution at the surface of the material is very 
challenging due to differences in curing between hydrophobic (e.g., air) and hydrophilic 
(e.g., aqueous) environments. When the materials are cured in the laboratory, a thin skin 
forms at the material/air interface, but this skin is not present when the materials are 
cured in a moist environment. Thus it is difficult to reproduce the in vivo pore size 
distribution at the surface of the composite under in vitro conditions.  At 35% and 47% 
porosities, the pores in the interior of the composite are comparable in size (183  90 m 
for the 35% porosity scaffold and 177  90 m for the 47% porosity scaffold), and do not 
appear to be inter-connected.  At 65% porosity, the pores are larger (701  317 m) and 
appear to be inter-connected, which is consistent with previous studies investigating non-
filled scaffolds.
29
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Figure IV.7: Scanning electron microscopy images of SDMBP/PUR scaffolds. 
(50wt% SDMBP/PUR foam scaffolds at (A) 35%, (B) 47%, and (C) 65% porosity. 
Allograft bone particles are traced in black. Scale bar represents 500 mm.) 
 
Working and tack-free times 
 The working and tack-free times were adjusted by varying the concentration of 
TEDA catalyst using the two-component process. At elapsed times shorter than the 
working time, the mixed components of the scaffold can be injected from the syringe and 
manipulated without disrupting the pore structure. As defined in Section 2.6, the tack-free 
time is the period of time required for the scaffold to sufficiently cure such that the 
surface can be touched with a probe that is subsequently removed without adhering to the 
surface.  As shown in Figure 4.8, the tack-free time of the SDMBP/PUR scaffolds 
(porosity 40%) varied between 10 – 20 minutes by reducing the TEDA concentration 
from 0.8 to 0.4 parts per 100 parts polyol (pphp). The working time varied from 4 – 8 
minutes over the same TEDA concentration range.  Working and tack-free times were not 
strongly influenced by water concentration, allograft surface chemistry, or the type of 
allograft. 
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Figure IV.8: The tack-free and working times of 50wt% SDMBP/PUR scaffolds with 
varying TEDA concentrations. 
(DMAEE and water concentrations were 0.6 and 4.0 pphp, respectively.) 
 
Viscosity Measurements  
 Figure 4.9 shows the initial dynamic viscosity of the MBP/PUR composite mixture, 
which ranged from 180-1200 Pa*s.  As expected, the MBP/PUR composite mixture 
exhibited the behavior of a shear thinning paste.   
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Figure IV.9: Initial dynamic viscosity of injectable MBP/PUR composites measured 
using an AR-G2 (TA Instruments) rheometer. 
The viscosity was measured dynamically with a frequency sweep from 0.1 to 100 rad/s 
and controlled strain amplitude of 0.02%. 
 
In vitro degradation   
 In vitro degradation data are presented in Figure 4.10.  At 30 weeks degradation 
time, the remaining mass of the scaffolds varied from 75 – 88 wt%. While there were no 
significant differences between the 30%, 40%, and 60% treatment groups, the 70% 
porosity material exhibited slower degradation after 20 weeks. No significant changes in 
the surface morphology of the composites were observed during this time period.   
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Figure IV.10: In vitro degradation of SDMBP/PUR scaffolds as a function of porosity. 
Samples were incubated in phosphate buffered saline at 378C and mixed end over end, 
and removed and weighed at each time point. 
 
In vivo osteoconductivity 
 A pilot study was performed in an athymic rat model to demonstrate injectability of 
the material and investigate its potential to support new bone formation.  The 40% 
porosity formulation was selected due to its suitable mechanical properties for weight-
bearing applications.  Considering that the manufacture of surface-demineralized 
allograft bone particles is challenging, as well as the observation that the differences in 
mechanical properties between SDBMP and DFMBP composites were minimal, H-MBP 
composites were selected for the animal study.  The allograft concentration was 45 wt% 
(31.1 vol%), which was the highest concentration which could be easily injected using a 
standard-bore syringe.  CT images of the H-MBP/PUR void filler injected into the 
femoral plug defects are shown in Figure 4.11.  For the images shown in Figures 4.11A-
B, the wound was immediately closed after injection, while for the images in Figures 
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4.11C-D, the wound was closed 15 minutes after injection.  Allograft within the 
composite, as well as evidence of new bone formation, can be seen in the materials.   
 
Figure IV.11: Microcomputed tomography images of human-SDMBP/PUR bone void 
filler injected into plug defects in the distal femurs of athymic rats 
Images were acquired after 3 weeks of implantation. (A, B) Wound closed immediately 
after injection. (C, D) Wound closed 15 min after injection. 
 
 Thin (e.g., 4 – 6 m) decalcified sections stained with fuchsin red/toluidene blue 
mixture are shown in Figures 4.12-14.  Figure 4.12A corresponds to the case where the 
material was injected and the wound immediately closed, while Figure 4.12 B and Figure 
4.13A correspond to the case where the wound was closed 15 minutes after injection.  
Figures 4.13s B, C, and D are higher magnification views of the material shown in Figure 
4.13A C.  Polymer is stained red, unresorbed allograft and cortical bone are stained light 
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pink, nuclei are stained purple, and collagen and connective tissue are stained blue.  
Direct apposition of the polymer (labeled “P) against the host bone (labeled “HB”) 
surface is evident in the histological sections, suggesting that the injected composite 
established close contact with the host tissue.  There is evidence of new bone growth 
adjacent to the material, as well as regions of new bone formation (labeled “RM”) near 
the host bone/composite interface and also deep into the interior of the composite.  These 
regions of new bone formation exhibit evidence of allograft resorption, osteoid (O) 
formation, collagen deposition, and new bone formation.  While there is extensive 
remodeling of allograft particles throughout the composites, some of the allograft 
particles (labeled “A”) were embedded in the polymer and thus did not remodel.  
 
Figure IV.12: Thin (e.g., 4–6 mm) decalcified sections of the composite bone void filler 
injected in bilateral femoral plug defects in rats 
Histology after 3 weeks of implantation stained with fuchsin red- toluidene blue. (A, B) 
Low magnification images showing host bone (labeled „„HB,‟‟ pink), voids (labeled 
„„V‟‟), residual polymer (labeled „„P,‟‟ red), allograft particles embedded in polymer that 
have not been resorbed (labeled „„A,‟‟ pink), regions of new bone formation (labeled 
„„RM,‟‟ purple) into the interior of the composite, osteoid, and bone marrow (labeled 
„„BM,‟‟ blue/purple) around the surface of the material. Panel (A) corresponds to the case 
where the wound was closed immediately after injection of the material, while panel (B) 
corresponds to the case where the wound was closed 15 min after injection. 
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Figure IV.13: Histology of implant of wounds closed after 15 minutes. 
( A: Low magnification of image showing host bone where the wound was closed 15 min 
after injection. (B–D) Higher magnification views of the implant shown in panel A. The 
labels „„P‟‟, „„A‟‟, „„RM‟‟, „„V‟‟, and „„HB‟‟ are defined as shown in Figure 4.12.) 
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Figure IV.14: Histology of areas of new bone formation. 
((A, B) Higher magnification of regions of new bone formation characterized by allograft 
(pink) resorption, cells (purple), and collagen deposition (blue). Panel (A) shows the 
cellular pathway in an interior region of the composite, while panel (B) shows the 
infiltration of cells into the composite from the bone marrow. In the center of panel (B) 
there is an allograftparticle undergoing active remodeling that appears to be embedded in 
polymer except for a small breach (labeled „„BR‟‟) where cells infiltrated along the 
allograft/polymer interface. The labels „„P‟‟, „„A‟‟, „„RM‟‟, „„V‟‟, and „„HB‟‟ are defined 
as shown in Figure 4.12.) 
 
Cells appeared to infiltrate the material both by entering open pores (labeled “V”), 
as well as via resorption of allograft particles, as shown in Figures 4.14s A and B. Figure 
4.14A shows the cellular pathway in an interior region of the composite, while Figure 
4.14B shows the infiltration of cells near the composite/host bone interface, where cells 
from the marrow (labeled “BM”) are observed to migrate into the composite.  In the 
center of Figure 4.14B there is an allograft particle undergoing active remodeling that 
appears to be embedded in polymer except for a small breach (labeled “BR”) where cells 
infiltrated along the allograft/polymer interface. Similarly, Figures 4.13s C and D show a 
large allograft particle that appears to be embedded in polymer except for two breaches 
where cells have begun to infiltrate along the allograft/polymer interface. These 
observations suggest that resorption of the allograft creates pores into which cells 
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subsequently migrate, thereby presenting an alternative pathway (in addition to migration 
through open pores) by which cells can infiltrate the composite. 
Discussion 
 
 Injectable biomaterials enable the filling of irregularly-shaped defects using 
minimally-invasive procedures. Injectable calcium phosphate bone cements, such as 
Norian SRS
®
 (Synthes), have received FDA approval as a bone void filler for orthopaedic 
applications.  In contrast to poly(methyl methacrylate) (PMMA), calcium phosphate 
cements are osteoconductive and biodegradable and have been shown to support bone 
ingrowth in vivo.   However, due to the small pore size (e.g., on the order of 1 m), the 
rate of cellular infiltration is slow with the material resorption and replacement rates 
inadequately matching the biology of the site.
24
  Furthermore, the materials are prone to 
brittle fracture which can lead to infectious complications.
23,30
  In this study, we have 
developed an injectable bone void filler comprising allograft bone particles and a 
reactive, two-component biodegradable polyurethane binder. By varying the amount of 
water added, the porosity of the composites ranged from <5 to 70%. The working and 
tack-free times were adjusted by varying the concentrations of the tertiary amine 
catalysts, and varied from 4 – 8 min for the working time and from 10 – 20 min for the 
tack-free time (similar to the setting time of a calcium phosphate cement). This tack-free 
time corresponds with the time in which the material can be injected and sutured without 
sticking to the tissue of the wound.  The dynamic viscosity of MBP/PUR injectable 
composites (180-1200 Pa*s) is comparable to that of injectable bone cements used in 
vertebroplasty (50-2900 Pa*s).
16
 General strategies to improve the injectability of pastes 
include the utilization of a broad particle size distribution and an increased viscosity of 
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the mixing fluid.
31
  MBP/PUR composites utilize both of these key attributes to facilitate 
a smooth injection.  As shown in the SEM micrographs (Figure 4.2), the  mineralized 
bone particles range in size from 100 – 1000 m.32  The viscosity of the LTI-PEG 
prepolymer is sufficiently high such that the allograft particles remain evenly distributed 
during the injection process, which is critical during the remodeling process as the 
particles create additional cellular pathways once resorbed.   
  As shown in Figure 4.3, the composition of the surface of the allograft particles 
has a dramatic effect on the porosity.  For SDMBP, the porosity approaches 50% even at 
very high water contents (8 pphp) in the absence of DMAEE, while for DFMBP, 50% 
porosity is attained at modest (4 pphp) water content. Furthermore, addition of the 
DMAEE blowing catalyst is required to increase the porosity of SDMBP composites 
above 50%.  Demineralized bone matrix (DBM) is well-known to be significantly more 
hygroscopic than allograft bone.  Therefore, the process of surface demineralization is 
conjectured to present a hygroscopic surface that serves as a water sink, which could 
account for the lower porosity observed for SDMBP composites.   
 The compressive stress-strain curves show that the 50 wt% SDMBP/PUR scaffolds, 
with the exception of the wet 60% porosity material, exhibited elastomeric properties up 
to 50% strain. The mechanical properties of the composites generally decreased after 
immersion in saline for 24 hours. In particular, the 60% porosity scaffolds were 
substantially weaker and failed under mechanical loading at strains less than 50%.  This 
is in agreement with a previous study reporting that the organic/inorganic interfacial 
bonding strength for composites comprising biodegradable polymers and hydroxyapatite 
could be reduced by 80–90% after 30 hours in a humid environment.28,33  Swelling of the 
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allograft component is also conjectured to contribute to the reduction in mechanical 
properties at >50 vol% allograft.   
 The tack-free (e.g., setting) times of the injectable composites were tunable in the 
range of 10 – 20 minutes by reducing the TEDA concentration from 0.8 to 0.4 pphp 
(Figure 4.8).  A short setting time is clinically desirable, since in many cases the wound 
cannot be closed until the material has sufficiently cured to preserve its shape and 
morphology.  The TEDA catalyst concentration also controlled the working time of the 
composites, which ranged from 4 – 8 minutes.  Clinically, it is desirable to maximize the 
working time and minimize the setting time to facilitate handling in the operating room. 
As shown in Figure 4.8, the working and setting times were related and decreased with 
increasing TEDA concentration, and the difference between these times also decreased 
with increasing TEDA concentration.  The allograft surface composition had a negligible 
effect on working and setting times, which is not surprising due to the fact that the onset 
of the gel point in the polymer network depends primarily on the polymerization 
reaction.
34
  Thus the cure properties of the allograft/PUR composites were comparable to 
the working (6 – 10 min) and setting (10 – 15 min) time requirements reported for 
injectable bone cements and void fillers.
35
 Furthermore, the effects of wound closure time 
did not appear to significantly affect new bone growth and cellular infiltration, which 
suggests that the waiting period after injecting the material could potentially be shortened 
by closing the wound prior to the setting time.  
 After 18 weeks (98 days) incubation time in saline, the SDMBP/PUR composites 
(ranging from 30 – 70% porosity) retained 86 – 92% of their initial weight.  The 
degradation time of the composites was slower than that measured for the pure polymer 
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scaffold (~50% of initial weight remaining after 14 weeks in vitro
28
) due to both lower 
porosity as well as the allograft component, which does not degrade in saline.  
Interestingly, the allograft composites degraded faster than porous PUR/TCP composites 
reported previously, where >95% of the material remained after 18 weeks incubation 
time in saline despite the lower TCP content (<10 vol%).
31
 The slower degradation time 
of the TCP composites is conjectured to result from the slower degradation rate of the 
polymer component.
18
 
 In a recent study, porous PUR scaffolds (without allograft) implanted in plug 
defects in rat femora exhibited rapid cellular infiltration and modest new bone formation, 
primarily around the perimeter of the scaffold in contact with host bone, at 4 weeks. 
However, PUR scaffolds without the allograft component are not suitable for injection, 
considering that it is not possible to control the pore size or expansion without adding a 
filler such as mineralized bone particles as there is reactivity with the filler and 
isocyanate groups. Furthermore, the absence of mineralized filler substantially reduces 
the mechanical properties of the cured composite. Other studies have shown that 
allograft/polymer composites support cellular infiltration through osteoclast-mediated 
resorption of the allograft phase. Non-porous allograft/polymer composites exhibited 
extensive cellular infiltration into the interior, as well as modest new bone formation, 
when implanted in femoral condyle plugs in rabbits.  Cellular infiltration was 
dramatically accelerated when the bone volume fraction approached the random close-
packing (RCP) limit (64 vol%), resulting in multiple allograft particle-particle contacts 
which presented a continuous osteoconductive surface through the implant.  In contrast, 
for PLLA/HA composites where the HA component was <40 wt% (~18 vol%), the rate 
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of cellular infiltration and new bone formation was very slow (e.g., 5 – 7 years) and 
dependent on the rate of polymer degradation.  The slower rate of cellular infiltration 
could be explained in part by both the relatively low HA volume fraction, as well as the 
small size of the HA particles (0.3 – 20 m with a mean of 3 m), which is below the 
optimal size range for remodeling by creeping substitution. Histological sections of 
allograft/polymer composites suggested that the allograft particles functioned as a 
porogen, wherein osteoclast-mediated resorption of the allograft created pores in the 
implant into which osteoblasts migrated and deposited new bone.  Osteotech has utilized 
cortical allograft bone fibers to achieve this effect in the commercially available Plexur 
platform, which are moldable, porous implants.  The Plexur platform has had substantial 
clinical success as it is widely accepted by surgeons with hundreds of surgical cases to 
date.  The two-component PUR system is moldable without a heating process.  
Furthermore, pores are naturally produced from the water reaction with isocyanate end 
groups.  We therefore reasoned that a combination of allograft particles and pores would 
facilitate rapid cellular infiltration and remodeling of the implant, while providing 
sufficiently high initial mechanical properties comparable to those of calcium phosphate-
based bone cements as well as trabecular bone.   
 Two-component PUR/TCP porous and non-porous composites have been reported 
to exhibit polymer degradation and new bone formation when implanted or injected into 
6  12 mm bilateral diaphyseal cortical defects in the femurs of sketally mature Merino 
wether sheep.  The yield strength varied from 6 – 13 MPa and the modulus from 270 – 
580 MPa; these mechanical properties are comparable to the PUR/allograft composites of 
the present study.  The materials implanted or injected in the sheep femoral plug defects 
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exhibited either 42 or 55% porosity, and in one case incorporated 20 wt% (8.8 vol%) 5 
m TCP.  New bone formation and osteogenic tissue were observed within the initial 
pores, as well as in the voids resulting from polymer degradation.  New bone formation 
progressively advanced towards the center of the materials with increasing implantation 
time (e.g., from 6 to 24 weeks), and cellular infiltration and new bone formation were 
more evident in faster degrading materials relative to slower degrading materials. 
Additionally, while the 5 m TCP particles effectively reinforced the mechanical 
properties of the composites, their small size precluded remodeling by creeping 
substitution. Taken together, these observations suggest that the rates of cellular 
infiltration and new bone formation were controlled by the rate of polymer degradation.  
In contrast, the PUR/allograft composites of the present study exhibited allograft 
resorption, cellular infiltration, collagen deposition, and new bone formation in the 
interior of the implant as early as 3 weeks.  This observation suggests that the 
combination of porosity and allograft bone particles provides connected pathways for 
cellular infiltration that are critical for remodeling.  Considering the large amount of 
polymer remaining throughout the composite, it is unlikely that the rapid remodeling 
could be attributed to polymer degradation. Furthermore, while the pores in the interior of 
the composite were sufficiently large (177  90 m) to support cellular infiltration, the 
SEM images suggest that the pores were not interconnected. Thus assuming that the pore 
size distribution at the surface of the composite is similar to that in the interior, it is 
unlikely that the rapid cellular infiltration and remodeling could be attributed to pre-
existing pores.  The histological sections (Figures 4.12-4.14) suggest that allograft 
remodeling by creeping substitution presented an alternative pathway for cells to 
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infiltrate the composite by migrating along the allograft/polymer interface.  These 
observations suggest that a continuous path for cellular migration into the interior of the 
implant may be achieved by a combination of pre-existing pores and allograft particles 
that are in the desirable size range (e.g., >100 m) for remodeling by creeping 
substitution.  
 Conclusions 
 
 Injectable, biodegradable allograft bone/polyurethane composite scaffolds have 
been synthesized with tunable porosities, mechanical properties, degradation rates, and 
setting and working times that are comparable to those of calcium phosphate bone 
cements.  When injected into femoral plug defects in athymic rats, the composites 
supported extensive cellular infiltration, allograft resorption, collagen deposition, and 
new bone formation at three weeks.  The combination of both initial mechanical 
properties suitable for weight-bearing applications, as well as the ability of the materials 
to undergo rapid cellular infiltration and remodeling, may present potentially compelling 
opportunities for injectable allograft/polyurethane composites as biomedical devices for 
bone regeneration.  
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CHAPTER V.  
Remodeling of allograft mineralized bone particle/polyurethane bone void filler 
composite with recombinant human bone morphogenetic protein (rhBMP-2) in a 
rabbit calvarium model 
 
 
Introduction 
 
 The treatment of craniofacial defects is a challenge as reconstruction must provide 
protection to the brain without while preventing infection and maintaining adequate 
cosmesis.
1
  Therefore, the restoration of form and function is a critical goal.  Craniofacial 
bones, which are generally flat bones, typically consist of two cortical plates with a core 
of trabecular bone that provides a minimum supply of osteoblastic precursor cells within 
the bone.  Furthermore, the curvature of craniofacial bones poses a challenge to restore 
form. Several alloplastic materials such as titanium meshes, polymethylmethacrylate, and 
hydroxyapatite ceramics have been used in the past to treat craniofacial defects.
2
  
However, issues such as slow resorption rates and postoperative infections can arise with 
the used of these treatments.
2
   
Craniofacial defects can arise from several causes, including trauma, tumor 
ablation, developmental anomalies, and infections due to needed surgical revisions.  As 
with all bone injuries, autograft bone is the gold standard as it is both osteogenic and 
osteoconductive.   However, limited supply and donor site morbidity are two significant 
disadvantages that hinder its use.
3
  Treatment of congenital defects in children between 
the ages of 2 and 10 are particularly challenging as defects have lost the ability to 
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spontaneously heal, and split calvarial grafts
4
 are not adequate due to the underdeveloped 
diploic space
5-7
.  On the battlefield, craniomaxillofacial injuries caused by explosive 
devices are characterized by open wounds and comminuted fractures, and in severe cases, 
complicated by avulsion of soft tissue and burns
8,9
. Currently, several treatments are 
being developed to address the need to treat craniofacial defects. 
 Several calcium phosphate cements such as Norian, Biopex, and BoneSource 
have been used clinically to treat craniofacial defects. Calcium phosphates are useful 
since they provide strength and chemically bond to bone
10
.   Norian is an injectable paste 
that comprises monocalcium phosphate, tricalcium phosphate, calcium carbonate and 
sodium phosphate and  hardens within the defect
11,12
.  The New Zealand white (NZW) 
rabbit critical sized defect (CSD) model has been used in several studies to investigate 
bone regeneration with Norian
11-13
.  A modest amount of new bone formation was 
observed in these studies.  New bone formation at 6 and 12 weeks was observed to be 
1.36% and 11.66 %, respectively
11,13
.  However, Norian calcium phosphate showed 
negligible penetration of cells into the material after 12 weeks and only appositional bone 
formation was observed 
11-13
.  Adverse effects on the soft tissue on the dura were 
observed in some cases due to fragmentation of the Norian material
11
. 
 Demineralized bone matrix (DBM) contains bone morphogenetic protein (BMP), 
which accelerates the differentiation of mesenchymal stem cells into osteoblasts.  It has 
been shown that DBM supports new bone growth in rabbit calvaria CSD
14
.  However, a 
carrier such as glycerol is needed to enhance the handling properties of granular DBM.  
DBM in conjunction with a delivery system has also been studied as a potential 
treatment.  A study with Grafton, a DBM putty from Osteotech, has shown 52.4% 
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mineral density in the rabbit calvaria CSD model after 12 weeks
1
.  In a similar study, 
DBM powder (47%) mixed with a poloxamer gel carrier (poloxamer 407) achieved 
44.3% new bone formation in the CSD defect
11
.  However, in contrast to calcium 
phosphates, DBM putties have weak mechanical properties and do not provide immediate 
protection to the brain
13
.   
 Recombinant human bone morphogenetic protein 2 (rhBMP-2) is a potent growth 
factor that has been widely studied for the treatment of CSDs.  Like DBM, it requires a 
carrier for delivery, which has been a challenge as the ideal carrier must maintain a 
sustained release of rhBMP-2 over a period of time due to its short half-life of 1-4 hours 
15-18
.  Since rhBMP-2 is an expensive protein, effective release strategies alleviate the 
cost to the patient by reducing required doses
16,19
.  Medtronic has obtained FDA approval 
for the use of rhBMP-2 for single-level anterior lumbar interbody fusion, marketed as 
INFUSE bone graft kits16,20.  The rhBMP-2 is adsorbed on the surface of sterile 
absorbable collagen sponges during soaking and released from the sponge once 
implanted in the defect.  However, in vitro studies have shown that collagen sponge can 
releases greater than 50% of rhBMP-2 within 24 hours
21
.   Calcium phosphates have also 
been investigated as potential delivery vehicles of rhBMP-2; however, brittleness and the 
lack of suitable porosity negate its effectiveness
18
.  A gel-based delivery system has been 
reported to effectively enhance spinal fusion in a rat model
22
, but gel systems typically 
lack initial strength.   
 To address the challenges of craniofacial repair, an ideal material should have the 
ability to fit complex defects (i.e., be moldable), provide temporary protection until tissue 
remodels, and enhance tissue regeneration with the delivery of biologics.
23
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Polyurethanes based on lysine-derived isocyanates are an attractive biomaterial as they 
are biocompatible
24,25
.  Allograft mineralized bone particle (AMBP)/polyurethane (PUR) 
composites, a two-component injectable system, have been investigated in both rabbit 
and rat distal femur models and have been shown to be biocompatible and support 
remodeling
26,27
.  In these studies, the AMBP phase provided a pathway for cellular 
infiltration by osteoclast-mediated resorption.  Cellular infiltration was accelerated by 
pores resulting from the blowing reaction that occurs when the isocyanate groups react 
with water, which allowed for migration of cells into pores.  In this study, the potential of 
injectable AMBP/PUR composites to enhance bone healing in the NZW rabbit calvarial 
CSD model was studied.  The composites incorporated 47% AMBP and 50% porosity.  
Delivery of INFUSE rhBMP-2 from the AMBP/PUR composites to accelerate bone 
formation was also studied.  
Materials and Methods 
 
Materials 
LTI-PEG prepolymer and polyester polyol were obtained from Ricerca 
Biosciences (Concord, OH), and Tegoamin 33 was received from Goldschimidt 
(Hopewell, VA).  The gelling catalyst triethylene diamine (TEDA) and dipropylene 
glycol (DPG) were purchased from Sigma-Aldrich (St. Louis, MO).  Ultrafoam collagen 
sponges were purchases from Davol (Warwick, RI).  An Infuse Bone graft kit was 
acquired from Medtronic (Minneapolis, MN).  Rabbit allograft mineralized bone particles 
(100-500 microns) were received as a gift from Osteotech, Inc. (Eatontown, NJ).  
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Preparation of rhBMP-2 
 A solution of rhBMP-2 (1.5 g/mL) was prepared by reconstituting rhBMP-2 
powder per mixing instructions provided with the Infuse kit.  The solution was aliquoted 
into vials to achieve 80 g/mL of active rhBMP-2 dose in each vial.  The vials were 
frozen at -80 C and lyophilized to achieve a powder.     
Synthesis of BVF 
The polyester polyol background comprised 60% caprolactone, 30% glycolide, 
and 10% lactide and had a molecular weight of 900 g mol
-1
 (6C3G1L900).  An index of 
130 was targeted to produce a BVF composite with a porosity of approximately 50% 
upon injection.  The TEDA catalyst was blended with DPG to yield a 10% solution of 
TEDA.  The appropriate amounts of polyol, AMBP (47 wt%), and LTI-PEG prepolymer 
were added to a mixing cup and mixed for 90 seconds.  The resulting paste was then 
added to the rhBMP-2 vial, followed by the addition of TEDA and mixed for 60 seconds.  
The resulting reactive paste had a working time of approximately 5 minutes and a cure 
time of 10 minutes.   
In vitro rhBMP-2 release study 
 A 2.5 g cylindrical BVF was prepared using with a dose of 50 g of rhBMP-2.  
Using previously published methods
27
, an appropriate amount of water was added to the 
foam to produce a porosity of 50%.  Discs of approximately 500 microns in thickness 
were cut from the BVF and placed in MEM media with 1% BSA.  Media was collected 
periodically over a 25 day period and analyzed using a BMP-2 Enzyme-linked 
immunosorbent assay (ELISA) to determine rhBMP-2 concentration.   
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Animal Study 
As shown in Table 5.1, four treatment groups were investigated in this animal 
study using skeletally mature New Zealand white rabbits. Following standard practices 
for aseptic surgery, a full-thickness calvarial defect was prepared in the parietal bones 
using a 15-mm surgical trephine for rabbits as described previously.
 
 The defects were 
treated according to the pre-determined randomization scheme.  An anteroposterior 
(anterior to the palpated occipital bone and posterior to the transverse line bisecting the 
ears) midline skin and periosteal incision was created along the palpated cranial vault (or 
external saggittal crest).   The length of the incision was 3 – 4 cm.  Periosteum was 
elevated with an elevator and retracted to expose the parietal bones and the transverse 
suture between the parietal and frontal bones.  A MicroAire surgical drill with a brass 
trephine was used to create the critical size defect (CSD) of 15mm during copious saline 
irrigation.  The location of the CSD is 1 – 2 mm distal to the transverse suture centered 
over the midline of the parietal bones.  The cranial cap was carefully removed posterior 
to anterior while using an elevator to separate the attached dura from the underside of the 
cap.  Pressure with sterile gauze was applied to stop excessive bleeding.  Photos were 
taken and either no treatment (for the negative control rabbits) or treatment (a material 
was added to fill the defect) was completed.  Collagen sponges were cut to fit the defect 
and soaked in the appropriate solution of rhBMP-2 for 10 minutes prior to application for 
a dose of 80 g per sponge.  Soft tissues were closed in layers using resorbable 3-0 
Dexon sutures to create 2 sets of continuous sutures. 
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Table V.1: Treatment groups for in vivo rabbit calvaria study. 
 6 weeks 12 weeks 
negative control n = 10 n=10 
Norian n = 10 n=10 
BVF n = 10 n=10 
BVF with rhBMP-
2 n = 10 --- 
 
X-ray Analysis 
 X-rays were acquired for each calvarium after extraction.  CTAn software was 
used to analyze the volume and density of bone for each treatment group.  A region 
identical to the size of the defect created during the original study was outlined on each x-
ray.  The percent of the defect filled by ossified tissue was measured to the pixels of gray 
to the total number of pixels in the defect area.  The bone density was determined by the 
ratio of the mean gray histogram (distribution of gray) to the defect to the mean 
histogram of the surrounding host bone.    
Histology and histomorphometry 
The calvaria were placed in a solution of 10% formalin followed by a series of 
ethanol dehydration.  The specimens were then embedded in methyl/butyl methacrylate.  
The resulting blocks were then sectioned using an Exakt system, producing 75-micron 
sections.  Resulting sections were stained with Sanderons‟ Rapid bone stain 
counterstained with Van Gieson.  Histomorphometry was completed using Image Pro 
Plus.  Residual polymer, allograft bone, and new bone formation were quantified for 
three zones, including both edges of the implant and the center region.   
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Results  
 
In vitro Release Study 
 Figure 5.1 shows an initial burst release of rhBMP-2 form the BVF scaffold 
between days 1 and 4.  Subsequently, a steady release was observed after day 4 with a 
cumulative amount of 20% rhBMP-2 released by day 25.   
 
Figure V.1: In vitro release kinetics of rhBMP-2 from BVF composite with 50% porosity 
and 47% AMBP. 
 
Animal Study 
 During the surgical procedure, either the Norian or BVF composite groups was 
injected in the defect, which had a volume of approximately 0.5 mL. A total of 0.25 mL 
of the AMBP/PUR bone void filler (BVF) composite was used to fill the defect as it 
doubled in size during curing.  In contrast, the Norian group developed cracks as it 
hardened before closing the wound.   
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Figure V.2: Surgical photos from the NZW rabbit calvaria CSD study 
( A: preparation of CSD, B: injection of Norian material showing material failure due to 
cracks, C: injection of BVF composite.) 
 
X-ray Analysis 
 X-rays (Figure 5.2) of the negative control defects showed minimal bone 
formation in the defect at both 6 and 12 weeks, as anticipated for a CSD.  Consistent with 
observations during surgery, x-rays of the Norian treatment group showed cracking of the 
material.  Bone ingrowth was observed around the perimeter of the BVF treatment groups 
with traces of bone in the center.  X-rays did not indicate any significant differences 
between the 6 and 12 week time points for the BVF composite treatment group.  The x-
rays of the BVF composite with rhBMP-2 showed a significant increase in new bone 
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formation within the defect.  In contrast, the x-rays of the collagen/rhBMP-2 showed 
minimum bone growth in the defect.   
 
Figure V.3: X-rays of rabbit calvaria at 6 and 12 weeks. 
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Figure V.4: X-ray of (A) collagen with rhBMP-2 and (B) BVF composite with the 
incorporation of rhBMP-2 at 6 weeks.   
 
 
 Figure 5.5 shows the results of the CTAn software analysis of the first three 
treatment groups.  A majority of the mineral content measured for the Norian treatment 
group derived from residual calcium phosphate and not new bone formation.   Therefore, 
little information could be inferred from CTAn analysis on the Norian groups.  CTAn 
analysis confirmed that there were no significant differences between the 6 and 12 week 
groups for the BVF composite groups.  The CTAn analysis included both new bone 
formation and allograft bone particles.  As expected, there was a significant difference 
between the negative control and the BVF composite groups.  There was no significant 
difference in the density of the mineral at 6 and 12 weeks for the BVF composite.  Figure 
5.6 compares the 6 week BVF and collagen groups in which AMBP were also included in 
the bone volume analysis.  BVF composites with rhBMP-2 showed a significant amount 
of bone volume in the defect; however, there were no significant differences in bone 
density over all the BVF composite groups.  As observed for the x-ray images, CTAn 
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analysis showed very little mineralization for the collagen/rhBMP-2 group.  However, the 
mineral density of the regenerated bone in the collagen/rhBMP-2 was consistent with the 
other treatment groups.   
 
Figure V.5: Percent of defect area filled and density measurements as measure by CTAn 
software. 
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Figure V.6: Percent of defect area filled and density measurements as measure by CTAn 
software. 
 
Histology 
 As expected, a fibrous scar filled the untreated defect at both time points (Figure 
5.7).  Histology indicates that there were no adverse responses to any of the treatment 
groups used in this study.  The Norian treatment groups (Figure 5.8) show appositional 
bone growth around the surface and between the cracks of the material as evident by the 
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mineralization stained in pink.  This pattern was the same for both the 6 and 12 week 
Norian groups.  However, there was no cellular infiltration in the material as there was no 
pathway for invasion.  Figure 5.9 shows histology of a BVF composite at the 6 week time 
point.  Cells, stained light blue, invaded the BVF composite via the pores of the material.  
At the host bone/implant interface new bone formed within the pores of the implant lined 
with osteoid which is stained blue.  There is a moderate amount of residual polymer, 
stained dark blue, within the implant cavity.  There was a moderate amount of 
overexpansion and lifting of the BVF composites due to the carbon dioxide blowing 
reaction that occurs during curing
27
.  Despite overexpansion, cells were still able to 
infiltrate the entire implant.  In contrast, histology from the 12 week BVF composite 
(Figure 5.10) showed extensive polymer degradation as well as new bone formation.  The 
BVF composite with rhBMP-2 showed extensive bone growth around the composite as 
well as throughout the pores of the material. The histology (Figure 5.12) of 
collagen/rhBMP-2 showed fibrous tissue and minimal new bone formation. High 
magnification images (Figure 5.13) show blood vessel formation within the implant 
cavity, as well as osteoclasts and osteoid. 
 Figure 5.14 shows the histomorphometry of the BVF treatment groups.  As 
expected, there are significant differences in the amount of new bone and residual 
polymer between 6 and 12 weeks.  Furthermore, the BVF incorporating rhBMP-2 
exhibited the greatest bone formation and polymer degradation.  The increased polymer 
degradation in the rhBMP-2 group is most likely due to development of blood vessels 
which deliver monocytes to the defect site.  Surprisingly, there was not a significant 
difference in the amount of allograft bone remaining in all of the treatment groups.  This 
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suggests that the AMBP is being resorbed at early time points to provide pathways of 
cellular infiltration.     
 
 
Figure V.7: Histology of untreated calvarium defect. 
 
 
Figure V.8: Histology of Norain treatment group in the calvarium defect . 
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Figure V.9: Histology of BVF composite treatment group in the calvarium defect at 6 
weeks. 
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Figure V.10: Histology of BVF composite treatment group at 12 weeks.  
 
 
 
Figure V.11: Histology of BVF composite treatment group with the incorporation of 
rhBMP-2 at 6 weeks.   
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Figure V.12: Histology of collagen treatment group with the incorporation of rhBMP-2 
at 6 weeks.   
 
 
Figure V.13: High magnification histology of BVF treatment group with the 
incorporation of rhBMP-2 at 6 weeks. 
(OB: old bone, OC: osteoclast, NB: new bone, BV: blood vessel.) 
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Figure V.14: Histomorphometry of the BVF treatment groups. 
 
Discussion  
 
 There are several rhBMP-2 release strategies being studied as potential clinical 
applications
15,16,18,22
.  These systems do not typically provide initial strength to the defect 
and require the support of an additional implant.  Furthermore, the release kinetics of 
these systems can be difficult to control.  The in vitro release kinetics of rhBMP-2 from 
the BVF composites shown a modest release (<10%) after 1 day.  It has been reported 
that initial bursts of kinetics of greater that 30% is non-ideal as clinical complications 
such as hematomas of soft tissues can occur
18,28
.  When implanted in vivo, it is expected 
that osteoclastic resorption of the AMBP phase provides an additional pathway for the 
release of rhBMP-2.  With this attribute, BVF composites are anticipated to under cell-
mediated release of rhBMP-2.    
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 The in vivo curing attributes of the BVF composites were superior to the Norian 
biomaterials considering the cracking of the Norian cements before wound closure, which 
has been observed with calcium phosphate cements from previous studies
11
.  This 
observation is expected as the pulsatile forces of the dura can have systolic normal and 
tangential stresses of 54.2 kPa and 345.4 kPa, respectively
29
.  Both materials cured within 
10 minutes of injection, providing early protection to the brain unlike DBM putties, 
which possess weak initial mechanical properties
12
.  However, studies have shown that 
the stiffness of Norian (80 N/mm) does not match that of bone (~130 N/mm) after 
implantation for 8 weeks, but is still significantly greater than the Novabone/DBM mix 
(~30 N/mm) at the same time point
12
.     
Surprisingly, the collagen/rhBMP-2 group did not stimulate a substantial amount 
(<30% mineralized) of new bone in the defect.  In a similar rabbit study,greater than 90% 
ossification after 6 weeks using collagen/rhBMP-2 was reported
7
.  In a primate CSD 
calvarium model, greater than 70% ossification as observed after 6 months
30
.  Both of 
these studies utilized a higher dose of rhBMP-2, greater than 400 g/mL.  However, it is 
anticipated that the defect would show more new bone formation than the untreated 
group.  The histology from this study suggests that the collagen degraded too quickly.  
Without a scaffold to support the osteoblastic cells, new bone formation is hindered.  As 
histology shows, Figure 5.12, the collagen implant was likely degraded prior to the onset 
of bone formation.   
 Histological sections showed extensive cellular infiltration for all of the BVF 
groups.  In contrast, the Norian group did not support cellular infiltration and essentially 
acted as a barrier to bone formation over the 12 weeks.  Bone was regenerated in all of 
143 
 
the BVF composite groups, as evidenced by the observation that new bone formation 
significantly progressed with time.  Interestingly, there was minimum residual PUR 
remaining at 12 weeks, and rhBMP-2 accelerated PUR degradation, which is conjectured 
to result from an increased presence of blood vessels.  Although there was a significant 
difference between new bone formation at 6 and 12 weeks, the amount observed was 
lower than expected, especially in the center of the implant.  At this later time point, the 
degradation of the PUR is anticipated to diminish the structural integrity of the BVF 
composites, since the majority of the bone ingrowth was observed around the perimeter 
of the defect and not in the middle.  Without new bone, allograft, or PUR remaining in 
the middle region of the implant, new bone formation could not progress due to the 
absence of a scaffold for new formation.  Mechanical stability is a key characteristic of 
successful biomaterials
31
, especially in the calvaria defect due to the pulsatile forces 
emanating from the dura
29
.  In contrast, histological sections of the BVF/rhBMP-2 group 
show a bridge of new bone covering the upper surface of the implant as well as new bone 
formation throughout the implant, suggesting the adequate delivery of rhBMP-2 from the 
material.  It is anticipated that this new bone formation would provide adequate support 
during the healing process as the PUR is degraded.    
 Extensive vascular formation in the defect was only observed in the BVF/rhBMP-
2 composite groups.  Several in vitro co-culture studies have shown that osteoblasts have 
the capability to regulate proliferation and differentiation of endothelial cells by changing 
pro-angiogenic cues such as VEGF via paracine signaling
32-34
.  Furthermore, this 
vascularisation is essential for bone induction
34
.  It is conjectured that the release of 
rhBMP-2 from the BVF composite acts to increase the population of osteoblasts, thereby 
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increasing the endothelial cell population creating vessel structures as shown in Figure 
5.13.  These vessel structures further supply the nutrients needed for cells to remodel in 
the interior of the implant. Since osteoclasts and osteoblasts are also coupled
35
, the 
population of osteoclasts is anticipated to increase, thereby accelerating resorption of 
allograft bone particles and allowing for additional release of rhBMP-2.   
 As the typical rhBMP-2 dose for rabbits is 400 g/mL16, it is encouraging that 
there was extensive new bone formation and vessel formation at a fraction of the 
recommended dose (80 g/mL).  This finding further suggests that the BVF composite 
platform is an efficient carrier for rhBMP-2 in vivo.  Improving the efficiency of the 
release of rhBMP-2 is a key factor in enhancing the cost-effectiveness of the growth 
factor
19
, making rhBMP-2 a more attractive option for bone tissue engineering.     
Conclusion 
 
 In vitro release studies have shown that rhBMP-2 has a sustained release from 
BVF composites.  BVF composites had a cure and working time comparable to 
injectable, fast-setting Norian, while displaying mechanical integrity during wound 
closure. BVF composites were shown to facilitate the ingrowth of new bone around the 
perimeter of the rabbit calvaria CSD.  Furthermore, the addition of a low dose of rhBMP-
2 (80 g/mL) accelerated new bone formation as new bone was observed throughout the 
implant while also increasing blood vessel formation. Injectable BVF composites are a 
promising injectable biomaterial capable of providing initial strength
27
, while sustaining a 
release of rhBMP-2.   
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CHAPTER VI.  
Low-porosity injectable allograft bone/polymer biocomposites incorporating 
rhBMP-2  
 
 
Introduction 
 
 Autograft bone is the clinical standard of care for treatment of bone defects due to 
its osteoinductive and osteogenic properties. However, its limited supply has prompted a 
search for suitable alternatives.  Numerous injectable biomaterials, such as calcium 
phosphate cements, have been developed as a substitute autograft, but they typically lack 
its osteogenic properties.  Incorporation of growth factors, such as recombinant human 
bone morphogenetic protein-2 (rhBMP-2), is an attractive option used to enhance the 
osteogenic properties of synthetic biomaterials.  However, the release of rhBMP-2 can be 
a challenge, as a sustained release is desirable to support bone healing during the initial 
stages.   
The optimal delivery of rhBMP-2 has been widely studied
1-6
 due to concerns 
regarding biosafety and cost-effectiveness
1,7
. Collagen and hydrogels have been 
extensively investigated as delivery systems for rhBMP-2
1,3,4,6
; however, there are few 
injectable weight-bearing platforms for recombinant human bone morphogenetic protein 
(rhBMP-2).  Allograft bone mineralized particle (AMBP)/polyurethane (PUR) systems 
have exhibited both biocompatibility as well as remodeling capabilities in vivo
8,9
.  An 
allograft bone particle/polyurethane (PUR) composite non-porous putty with a release 
mechanism of rhBMP-2 that is more responsive to the surrounding cellular environment 
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would aid in the efficient delivery of rhBMP-2.  Both non-porous and porous platforms 
have been studied.  In the rabbit distal femur model, compression molded AMBP/PUR 
with allograft loadings approaching the random close-packing limit (64 vol%) showed 
rapid osteoclast-mediated resorption of the AMBP phase, thereby providing a pathway 
for cellular infiltration.  However, due to the relatively slower rate of new bone 
formation, large resorption gaps were observed near the host bone/implant interface
8
.  In 
the rabbit calvaria critical size defect (CSD) model, injectable AMBP/PUR bone void 
filler (BVF) composites (~50% porosity) demonstrated modest new bone formation 
around the perimeter of the implant.  When an 80 g/mL  dose of INFUSE (rhBMP-2) 
was added to the composite, new bone formation was enhanced throughout the interior of 
the composite.  This dose was significantly lower than the recommended dose for rabbits 
(400 g/mL1).  To study the effects of higher doses, two studies are currently being 
completed incorporating two doses of rhBMP-2 (100 g/mL and 400 g/mL) at 6 and 12 
weeks.     
Materials and Methods 
 
Materials 
LTI-PEG prepolymer and polyester polyol were obtained from Ricerca (Concord, 
OH), Tegoamin 33 was received from Goldschmidt (Hopewell, VA), and recombinant 
human bone morphogenetic protein (rhBMP-2) was purchased from R&D systems 
(Minneapolis, MN).  Trehalose dehydrate, heparin sodium salt, acetonitrile, and 
trifluoroacetic acid (TFA) was purchased from Sigma Aldrich(St. Louis, MO).  Rabbit 
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allograft mineralized bone particles (100-500 microns) were received as a gift from 
Osteotech, Inc. (Eatontwon, NJ).   
Preparation of rhBMP-2 
 The rhBMP-2 was supplied as a solution which comprised 35% acetonitrile and 
0.1% TFA.  A separate acetonitrile/TFA solution was prepared containing a ratio of 10:1 
of trehalose dehydrate:heparin sodium.  The rhBMP-2 and trehalose mixtures were 
combined such that the ratio of rhBMP-2 to trehalose was 1:125.  The resulting mixture 
was distributed in glass vials and frozen at -80 C in preparation for freeze-drying, which 
produced a powder. 
Synthesis of AMBP/PUR Putty 
 The polyester polyol backbone comprised 60% caprolactone, 30% glycolide, and 
10% lactide and had a molecular weight of 900 g mol
-1
 (6C3G1L900).  The appropriate 
amounts of polyol, AMBP, and LTI-PEG prepolymer were added to a mixing cup and 
mixed for 90 seconds.  The target index was 130 and catalyst concentration of Tegoamin 
33 was 5500 ppm.  The resulting paste was then added to the rhBMP-2 vial and mixed for 
60 seconds. The filler content (AMBP and rhBMP-2 powder) was kept at constant 70 
wt% for each putty treatment group (Table 6.1).   The resulting reactive paste had a tack-
free (i.e., cure) time of approximately 10 minutes.   
Mechanical Properties 
 Cylindrical samples of each treatment group were prepared for mechanical 
testing.  The reactive paste was transferred into cylindrical plastic cups and a 1 pound 
weight (20.7 psi) was placed on the material for 10 minutes.  The resulting cylinders were 
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placed in a vacuum oven at 37
o
C overnight and removed from the plastic cups.  After 
cure, the cylinders were removed from the cups and cut using a Buehler saw to produce 6 
mm x 12 mm cylinders.  Three different formulations were synthesized as summarized in 
Figure 6.1.  After 24 hours of hydration in phosphate buffered saline (PBS), the rods were 
tested using a MTS 898 using compression.    
 
Figure VI.1: Mechanical properties of AMBP/PUR putty system. 
 
Animal Study 
 Forty-two New Zealand White (NZW) rabbits weighing between 3.8 and 4.1 kg 
were used in this study.  All surgical and care procedures were carried out under aseptic 
conditions per the approved IACUC protocol.  The AMBP/PUR putty components were 
gamma irradiated using a dose of approximately 25 kGY.  Glycopyrrolate was 
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administered at 0.01 mg/kg IM followed by ketamine at 40 mg/kg IM.  Bilateral defects 
of approximately 6 mm diameter by 11 mm in depth were drilled in the metaphysis of the 
distal femurs of each rabbit. AMBP/PUR plugs from each treatment group, Table 6.1, 
were subsequently injected into each defect using a 1 mL syringe.  Treatment groups for 
each composite were dispersed randomly among the rabbits.  The rabbits were euthanized 
at both 6 and 12 week time points using Fatal-plus (2.2 mL/10 kg) intra-venously.   
 
Table VI.1: Treatment groups of in vivo rabbit study. 
  
rhBMP-2 
(g/mL) 
6 
weeks 
12 
weeks 
empty 0 n=6 n=6 
AMBP putty 0 n=10 n=10 
AMBP putty-L 100 n=10 n=10 
AMBP putty-
H 400 n=10 n=10 
 
CT Data 
 A CT40 (SCANCO Medical, Basserdorf, Switzerland) was used to acquire 
images of the extracted femurs.   
Histology 
 After fixation, the femurs were embedded in Technovit 7200 and 200-m sections 
were cut from the resulting blocks using an Exakt band saw.  The sections were then 
ground and polished using an Exakt grinding system to less than 100 m and stained with 
Sanderson‟s rapid bone stain counterstained with van Gieson.  Old allograft bone stained 
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light brown, while new bone stained pink with dark blue osteocytes within the matrix.  
The polymer was stained dark blue, while cells were stained light blue.   
Results  
 
Mechanical Properties 
There were no significant differences between the mechanical properties of each 
treatment group as the strength and modulus values ranged from 24.2-28.1 MPa and 
357.3-503.0 MPa, respectivley.  These compressive strength is comparable to that of 
trabecular bone, which ranges from 4-12 MPa
10
. 
CT Data 
 The CT images of the AMBP/PUR treatment groups are presented in Figure 6.2.  
The absence of a resorption front was observed for all of the AMBP/PUR treatment 
groups without rhBMP-2 (Figure 6.2A).  However, remodeling for this group was the 
slowest and least extensive when compared with the groups that incorporated rhBMP-2.  
Approximately 10% of the AMBP/PUR group incorporating low rhBMP-2 exhibited 
resorption gaps.  In comparison, 30% of the high rhBMP-2 group exhibited resorption 
gaps as shown in Figure 6.2D.   
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Figure VI.2: CT images of AMBP/PUR composites. 
(A: CT images show extensive remodeling of AMBP/PUR composites at twelve weeks 
(A: 0 g/mL, B: 110 g/mL, C: 440 g/mL,) and six weeks (D: 440 g/mL).) 
 
Histology 
 Histological sections (Figure 6.3) of the AMBP/PUR putty treatment group 
showed extensive new bone formation and cellular infiltration throughout the implant.  
The original border between the host bone and implant is indistinguishable.   The high 
A
B
C
D
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magnification view (Figure 6.3B) shows connectivity between new bone and allograft 
bone particles and suggests a creeping substitution remodeling mechanism.   
 
 
Figure VI.3: Histology from the ABMP/PUR putty treatment group with no rhBMP-2. 
(A: low magnification (A: allograft bone, NB: new bone, C: soft tissue, P: residual 
polymer), B: high magnification view at implant-host bone boarder.)  
 
Discussion  
 
AMBP/PUR biocomposites exhibited compressive strengths ranging from 27.2-
33.2 MPa, which are comparable to trabecular bone strength.  Figure 1 shows CT 
images for all treatment groups. The CT image for the biocomposite at 12 weeks 
without rhBMP-2 is shown in Figure 1A, and is characterized by extensive remodeling 
with negligible resorption gaps. A similar pattern was observed at 6 weeks, although the 
fraction of residual allograft particles that had not been remodeled was higher. These 
observations contrast with a previous study where compression-molded biocomposites 
incorporating 79 wt% allograft showed substantial resorption after 6 weeks in a rabbit  
femoral condyle plug model.
8
  As reported previously, cells infiltrated the biocomposite 
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by creeping substitution, wherein the allograft component is first resorbed by osteoclasts, 
followed by infiltration of cells and new bone formation.
8
  The rhBMP-2 is conjectured 
to be released from the polymer into the newly formed pores resulting from allograft 
resorption. Incorporation of rhBMP-2 (Figure 6.2B-D) enhanced new bone formation at 
12 weeks relative to the biocomposite without rhBMP-2, as evidenced by the presence of 
fewer allograft bone particles (irregularly shaped white particles).  Similar results were 
observed at 6 weeks. However, approximately 30% of the samples incorporating a high 
dose of rhBMP-2 displayed extensive areas of resorption at 6 or 12 weeks, as shown in 
Figure 6.2D. Similar regions of osteoclast-mediated resorption have been reported for 
doses of rhBMP-2 exceeding by a factor of 3 the recommended dose delivered on an 
ACS sponge in a sheep femoral condyle plug model.
11
 Figure 6.4 is a diagram of the 
proposed mechanism of remodeling.  The initial release of rhBMP-2 from the 
AMBP/PUR composites stimulates the differentiation of osteoprogenitor cells to 
osteoblasts, which subsequently regulate osteoclast differentiation through production of 
Receptor Activator for Nuclear Factor κB ligand (RANKL).12,13  The increased osteoclast 
population results in accelerated resorption of the AMBP filler, which consequently 
increases rhBMP-2 release through the creation of pores. In addition to its role of indirect 
regulation of osteoclasts through RANKL, rhBMP-2 can also directly stimulate osteoclast 
differentiation
11,14-16
, and the concentration of rhBMP-2 must be maintained below a 
threshold to prevent excessive resorption.  The results from this study suggest that the 
high dose of rhBMP-2 (400 g/mL) is near this threshold, as evidenced by the relatively 
high frequency (~30%) of samples showing resorption gaps. 
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Figure VI.4: Critical interactions of AMBP/PUR putty. 
An analogous “control loop” summarizing the critical interactions that occur during the 
remodeling of the AMBP/PUR putty with rhBMP-2 incorporation. 
 
Interestingly, in this study the high dose was the typical dose for rabbits, suggesting that 
the release mechanism of rhBMP-2 from the biocomposite may reduce the minimum 
effective dose required to enhance bone healing. 
Conclusions 
 
 Injectable allograft bone biocomposites supported bone remodeling with minimal 
resorption gaps in a rabbit femoral condyle plug model. Release of rhBMP-2 
corresponding to 25% of the typical dose enhanced remodeling of the biocomposite, 
while some of the composites showed resorption gaps at the high dose of rhBMP-2 
corresponding to the typical dose. These results suggest that the release efficiency of 
rhBMP-2 from the AMBP/PUR composites can reduce the dose of rhBMP-2 that yields 
optimal bone formation. Thus the allograft/polymer biocomposites may be a promising 
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approach for developing an injectable biomaterial that maintains its initial weight-bearing 
properties during remodeling.   
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CHAPTER VII.  
Conclusions 
 
 
 Polyurethane (PUR) composites derived from a lysine triisocyanate and polyester 
polyols have provided a versatile platform for a family of novel biomaterials for bone 
tissue engineering.  Through the manipulation of system parameters such as filler, polyol 
molecular weight, porosity, and growth factor incorporation, these PUR composites 
displayed an array of both mechanical and in vivo remodeling properties.  Furthermore, 
PUR composites can be utilized as either a prefabricated implant or an injectable two 
component system. Table 7.1 summarizes the platforms described in this work. 
Table VII.1: Summary of PUR Composites 
platform porosity filler 
filler 
wt% 
strength 
(Mpa) 
modulus 
(Mpa) 
implant < 5% HA/TCP 79% 107-172 3000-6000 
implant <5% AMBP 79% 59.6-87 2500-3600 
injectable 40-50% AMBP  47% 1-13 7-400 
injectable <5% AMBP 70% 24.2-28.1 357.3-503.0 
 
 Fabricated non-porous implants utilized a particulated phase of filler by meeting 
the random closed packing (RCP) limit of spheres (64 vol%).  Compression molded 
calcium phosphate (CaP)/PUR composites exhibited mechanical properties  suitable for 
weight-bearing applications and were shown to be biocompatible in both in vitro and in 
vivo studies.  In a more extensive study on compression molded allograft mineralized 
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bone particle (AMBP)/PUR composites, mechanical properties were tuned by varying the 
molecular weight of the polyol used during synthesis.  Furthermore, osteoclast-mediated 
resorption was shown to provide a pathway for cellular infiltration in vivo.   
 Injectable, porous, weight-bearing AMBP/PUR bone void filler (BVF) 
composites were synthesized by utilizing the carbon dioxide blowing reaction that occurs 
when isocyanates are exposed to water.  Mechanical properties were tuned in this system 
with the ability to control porosity.  Furthermore, working time and cure time were 
controlled by manipulating catalyst concentration.  In vivo studies demonstrated that the 
pores in the AMBP/PUR BVF composite system provided a primary pathway for cellular 
infiltration while the AMBP provided a secondary pathway via osteoclast-mediated 
resorption.  AMBP/PUR BVF composites demonstrated remodeling potential in the 
rabbit calvaria critical sized defect (CSD) model with a modest amount of new bone 
formation.  When recombinant human bone morphogenetic protein (rhBMP-2) was 
incorporated in the AMBP/ PUR BVF composite, the amount of new bone formation was 
enhanced in the rabbit CSD calvaria model, suggesting that the system is an adequate 
delivery vehicle for growth factors.   
 Injectable AMBP/PUR putty supported bone remodeling with minimal resorption 
in a rabbit femoral condyle plug model. Release of rhBMP-2 corresponding to 25% of the 
typical dose enhanced remodeling of the biocomposite.  Thus, the AMP/PUR putty could 
make a profound impact on the delivery strategies rhBMP-2 and other growth factors.  
The AMBP/PUR putty may be a promising approach for developing an injectable 
biomaterial that maintains its initial weight-bearing properties during remodeling. 
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 The data from this work supports the use of lysine-based PUR as a treatment for 
craniofacial and orthopaedic defects.  As it is injectable, this platform is attractive 
because it is minimally invasive. In vivo studies have demonstrated that they are 
osteoconductive.  Furthermore, they exhibit osteoinductive properties with the 
incorporation and release of rhBMP-2.  This platform could be used to fulfill the clinical 
need for treating challenging fractures in which traditional grafts fail to facilitate healing.   
 There are several opportunities for the continued evolution of this platform.  The 
mechanical properties can be enhanced by the comminuted study of the interaction 
between the allograft bone and PUR phase of the composites since there are a myriad of 
agents that can be grafted on the surface of the bone.  Also, a further investigation of the 
in vivo release kinetics of rhBMP-2 from the PUR composite platform could lead to 
further optimization of the material.  Implantable PUR scaffolds without AMBP have 
been fabricated successfully as a dual delivery system for rhBMP-2 and antibiotics.  
Thus, the dual delivery of such biologics from the AMBP/PUR composites would be a 
significant accomplishment in the treatment of wounds that are infected (e.g., battlefield 
injuries), which compromises the normal healing.   
 
 
 
